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ABSTRACT 
DONEPEZIL’S EFFECT ON CARDIAC FUNCTION IN PATIENTS WITH 
ALZHEIMER’S DISEASE THROUGH AN IN VIVO, NON INVASIVE MEASURE 
OF CARDIAC AUTONOMIC FUNCTION 
 
Lewis Patrick Hackett 
Old Dominion University, 2015 
Director: Dr. Serina A. Neumann 
The aim of the current study was to explore the effects of the medication 
Donepezil (Aricept®) on cardiac autonomic function for individuals diagnosed with mild 
to moderate (probable) Alzheimer’s disease (AD). Using age (± 3 years) and gender 
matched controls, differences in heart rate variability (HRV) among individuals with 
Alzheimer’s disease were compared to healthy controls over a period of six months 
(session 1 [baseline], session 2 [3 months], and session 3 [6 months]) in both supine and 
standing positions. HRV was obtained through frequency-domain (Low Frequency 
Power, High Frequency Power, RMSSD, LF/HF Ratio) and time-domain (six minutes) 
measures using ECG technology. Data were analyzed using 2x2x2 (AD group n= 12; HC 
group n= 12) and 2x2x3 (AD group n= 8; HC group n= 8) repeated measures 
ANCOVA’s while controlling for age, gender, body mass index (BMI), blood pressure, 
medications, dose of Donepezil (Aricept®), alcohol use, caffeine use, and physical 
activity. Results from the ANCOVA did not reveal statistically significant between group 
differences for the HRV frequency-domain measures. However, data indicated a trend 
towards greater reductions in normalized high frequency power (parasympathetic 
depression) and greater increases in normalized low frequency power (sympathetic 
exacerbation) among the AD group versus healthy controls at all three time points despite 
the use of Donepezil (Aricept®).   
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CHAPTER I 
INTRODUCTION 
The aim of the current study was to explore the effects of the medication 
Donepezil (Aricept®) on cardiac autonomic function for individuals diagnosed with 
Alzheimer’s disease (AD) and taking the medication Donepezil (Aricept®). Donepezil is 
a widely used cholinesterase inhibitor (ChEls) that is designed to increase cholinergic 
function among persons with mild to moderate AD. Cholinergic function regulates 
cardiac autonomic activity via the sympathetic nervous system (SNS) and the 
parasympathetic nervous system (PNS). Cholinergic function also plays an integral role 
in neurocognitive function. Depletion of cholinergic resources often results in cardiac 
autonomic dysfunction and neurocognitive impairment in persons with AD (Allan et al., 
2006; Bartus, 1999; Giubilei, et al., 1998; Toledo & Junqueira, 2008, 2009; Zulli et al., 
2005). Cardiac autonomic dysfunction generally refers to the imbalance of the 
sympathetic and parasympathetic nervous system. This imbalance is a recognized risk 
factor for cardiovascular mortality, characterized by higher risk of arrhythmias, 
parasympathetic depression, syncope, and sudden death (Allan et al., 2007; Kleiger, 
Miller, Bigger, & Moss, 1986; Schliebs & Arendt, 2006). Previous research has indicated 
some potential cardio-protective benefits of taking the medication Donepezil, and this is 
of particular interest in the present study. 
As research has demonstrated that individuals with AD often present with cardiac 
autonomic dysfunction, a growing body of evidence has supported the use of heart rate 
variability (HRV) measures in identifying cardiac autonomic dysfunction in persons with 
AD (Allan et al., 2007; Balocchi et al., 2006; Da Costa Dias Dias, Da Silva, De Moraes, 
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& Caramelli, 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; McLaren, Allen, 
Murray, Ballard, & Kenny, 2003; Siepmann, Mück, Engel, Rupprecht, & Mück-
Weymann, 2006; Task Force on Heart Rate Variability, 1996; Zulli et al., 2005). Heart 
rate variability (HRV) is frequently measured using non-invasive electrocardiogram 
(ECG) technology. This typically involves the patient wearing a heart rate sensor 
positioned close to the heart and a receiver is then positioned in close proximity to the 
sensor. In its most basic form, HRV refers to the fluctuation of intervals between 
consecutive heart beats as well as the fluctuation between consecutive instantaneous heart 
rates (Task Force on Heart Rate Variability, 1996). The HRV algorithm is not necessarily 
a measure of heart beats, but is rather a measure of the time and variation between beats 
(Task Force on Heart Rate Variability, 1996). This variation between beats is referred to 
as inter beat interval and is measured in milliseconds (ms). HRV more generally 
describes the variations in both heart beat intervals (RR intervals) and heart rate cycles 
(instantaneous heart rate) over a designated time frame. It is the variations in HRV 
intervals that are of particular interest here, as they represent changes in cardiac 
autonomic activity (Bernardi et al., 2011).  
 Using HRV technology, frequency-domain and time-domain (e.g., six minutes) 
measures can be used to provide an algorithm that represents cardiac autonomic output. 
ECG technology provides frequencies that reflect different levels of cardiac outflow and 
these include; very low frequency (0–0.04 Hz), low frequency (0.04–0.15 Hz), and high 
frequency (0.15–0.50 Hz) spectral bands. Low frequency (LF) output provides a measure 
of sympathetic and parasympathetic nervous activity, while high frequency (HF) output 
provides an exclusive measure of parasympathetic (cholinergic) nervous activity (Allan et 
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al., 2007; Task Force on Heart Rate Variability, 1996). In addition to this, the LF/HF 
ratio is computed and can be used as a measure of sympathovagal balance to reflect 
sympathetic modulation (Task Force on Heart Rate Variability, 1996). Frequency-domain 
measures have yielded significant results in a number of studies looking at cardiac 
autonomic function in persons with AD (Allan et al., 2007; Da Costa Dias et al., 2013; 
Giubilei et al., 1998; Masuda & Kawamura, 2003; Umegaki & Khookhor, 2013; Zulli et 
al., 2005). The most commonly used time-domain measure includes the mean squared 
differences of successive R-R intervals (RMSSD). This is used as a measurement to 
estimate the high frequency variations in heart rate (Toledo & Junqueira, 2008). It is 
commonly perceived that a regular heartbeat is a sign of strong cardiovascular health. 
However, the rhythm of a healthy heart or the successive cardiac cycle length is 
characterized by significant variability in healthy individuals. Therefore, normal and 
healthy heart rate is characterized by more variability and reductions in variability are 
often indicative of disease conditions (Sharma, Paudel, Singh, & Limbua, 2009). More 
specifically, greater high frequency (HF) HRV is an indicator of more healthful cardiac 
autonomic functioning, and those with AD tend to present with lower high frequency 
(HF) output (or parasympathetic depression; Sharma, Paudel, Singh, & Limbua, 2009; 
Toledo & Junqueira, 2008).   
The aim of the present study is to not only explore the differences in cardiac 
autonomic function in persons with AD compared to healthy controls, but to also explore 
the effects of the cholinesterase inhibitor (ChEl) Donepezil on cardiac autonomic 
function. Research has indicated potential cardiac autonomic benefits when using the 
popular cholinesterase inhibitor Donepezil (Nordstrom, Religa, Wimo, Winblad, & 
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Eriksdotter, 2013; Umegaki & Khookhor, 2013). The medication Donepezil 
hydrochloride (Aricept®) is one of the most popular ChEls used to treat cognitive 
impairment among persons with AD. ChEls such as Donepezil operate by preventing 
acetylcholine from being hydrolyzed thus increasing cholinergic resources. As 
cholinergic transmission is a mechanism involved in the regulation of the autonomic 
nervous system, it is hypothesized that Donepezil may provide some additional cardio-
protective benefits. These cardio-protective benefits can be assessed through changes in 
HRV as measured by ECG technology.  
Previous research has identified differences in cardiac autonomic function 
between individuals with AD versus healthy controls. Toledo & Junqueira (2008) and 
Zulli et al (2005) monitored cardiac autonomic function via ECG technology among 
those with AD, but in the absence of ChEl treatment. Both authors found significant 
differences in HRV between AD participants and healthy controls such that those with 
AD demonstrated parasympathetic depression (suggesting lower cholinergic function) in 
comparison to healthy controls. The authors of both studies assessed HRV at a single, 
fixed, time frame. The present study however, will extend the research from a single, 
fixed, time frame to look at changes in HRV over a period of six months. HRV data will 
be obtained at three different time points; baseline (session 1), and at three (session 2) 
and six month (session 3) follow-up intervals. Despite the single time-frame (cross 
sectional) design in the previous work, studies support the need for further investigation 
into cardiac autonomic dysfunction in persons with AD and support the use of ECG 
technology in obtaining HRV data.  
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Previous research has also shown that Donepezil stabilizes HRV among 
participants with AD by increasing parasympathetic nervous activity and decreasing 
sympathetic nervous activity (Giubilei, 1998; Umegaki & Khookhor, 2013). Giubilei et al 
(1998) explored the effects of a now discontinued and no longer available cholinesterase 
inhibitor (eptastigmine) on cardiac autonomic function via ECG technology over a period 
of one month. Participants included 12 individuals who were diagnosed with probable 
AD and 10 healthy controls. The AD group participants were prescribed the 
cholinesterase inhibitor (eptastigmine) for one month. HRV recordings were obtained 
before and after ChEl treatment in both resting and tilting positions. The tilting position is 
often used to study heart rate abnormalities by positioning the participant at different 
angles (e.g., 90 degrees; Kochiadakis, et al., 1998). This change in positioning often 
causes a decrease in high frequency (HF) HRV and subsequent vasovagal syncope (light-
headedness; Efremov, Brisinda, Venuti, & Iantorno, 2015). Results from the study 
indicated that both low and high frequency power generated by the AD group in the 
tilting position were similar to that of healthy controls following one month of ChEl 
treatment. However, major limitations to this study include the use of a now discontinued 
ChEls. According to the Alzheimer’s Association (2013), eptastigmine was discontinued 
by the Food and Drug Administration (FDA) due to its potentially harmful hematologic 
(blood related) adverse effects. This included reductions in red and white blood cells 
(pancytopenia) and the development of granulocytopenia (abnormally low concentration 
of granulocytes in the blood; Braida & Sala, 2001). Therefore, this medication is no 
longer available for use. The lack of FDA approval and negative side-effects associated 
with the medication certainly undermine its treatment efficacy and this is a limitation of 
6 
  
the study. Nonetheless, this study demonstrates some of the potential cardiac benefits 
associated with ChEl treatment.  
Additional limitations of the Giubilei et al (1998) study include the limited time 
frame in which HRV was monitored (one month). Previous studies have indicated that 
the benefits of Donepezil tend to be more evident after six weeks of ingestion. For 
example, a study by Rogers et al (1998) looked at changes in cognitive function over a 
period of 24 weeks (six months) among those with mild to moderate AD who were 
treated with Donepezil versus placebo-controls. At six weeks of using the medication, the 
authors reported no significant differences between those taking Donepezil versus healthy 
controls. However, after six weeks, cognitive performance for the Donepezil-treated 
participants improved with time whereas the placebo group showed significant 
deterioration (Rogers, 1998). According to the author, the beneficial effects of Donepezil 
were most pronounced at the 12 week visit and these effects persisted with no decrease in 
magnitude at weeks 18 and 24 (Roger, 1998). Other researchers have also demonstrated 
greater gains in cognitive function with Donepezil use after 24 weeks (six months; Mohs 
et al., 2001) while other researchers have identified more immediate gains in cognitive 
function (Feldman, 2001; Umegaki & Khookhor, 2013). The present study will explore 
changes in HRV among persons with AD who are taking Donepezil versus healthy 
controls over a period of six months. Participants’ HRV will be recorded at baseline and 
at three month and six month time points, for a total of three sessions.  Each session must 
be within one to two weeks of the three month mark. Therefore, each session occurs 
every three months (± two weeks). Based on the research by Feldman, 2001; Mohs et al., 
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2001; Rogers, 1998), this will provide more than adequate time for Donepezil to reach a 
therapeutic dose.  
Results from these aforementioned studies suggest positive gains in cognitive 
function as a result of taking Donepezil which may also reflect an increase in cholinergic 
function. As cholinergic function influences both cognitive function and cardiac 
autonomic function, it is probable that HRV may also improve more significantly at six 
months of taking the medication. Thirdly, although the authors used the tilting position to 
measure HRV as recommended by the Task Force on Heart Rate Variability (1996), LF 
and HF indices have been shown to change in different positions and under different 
conditions such as sitting to standing (Risk, Broadbridge, & Cohen, 2001; Task Force on 
Heart Rate Variability, 1996). Obtaining HRV readings from a still resting position 
(supine) to a standing position (orthostatic challenge) can help to identify any significant 
changes in SNS and PNS activity (Aysin & Aysin, 2007; Risk, Broadbridge, & Cohen, 
2001). The present study will employ two commonly used and recommended resting 
positions when measuring HRV (supine and standing), and will utilize the participants 
respiration when calculating HF HRV (Aysin & Aysin, 2007; Risk, Broadbridge, & 
Cohen, 2001; Task Force on Heart Rate Variability, 1996). The adjustment using 
respiration in a HRV algorithm is known as respiratory sinus arrhythmia (RSA). The 
RSA integrates changes in heart rate during inhalation (heart rate increases) and 
exhalation (heart rate decreases). Respiratory linked variations in heart rate usually occur 
in the high frequency (HF) range (Lehrer, Vaschillo, and Vaschillo, 2000). RSA has been 
shown to provide a more accurate index of cardiac vagal tone and parasympathetic 
activity (Grossman & Taylor, 2006).  
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In contrast to the Giubilei et al (1998) study, Masuda & Kawamura (2003) 
explored changes in HRV using a 24-hour ECG among individuals diagnosed with AD 
and who were taking the medication Donepezil for six weeks. The participants were 
initially taking 3mg of Donepezil which was later titrated to 5mg (after one week) and 
remained at this dose for six weeks. Results from the study indicated reductions in LF 
and HF power as a result of Donepezil treatment six weeks after beginning the 
medication. The reduction in the HF component was also greater than the reduction in the 
LF component, indicating a decrease in PNS activity (and reduced cholinergic activity) 
over the period of six weeks despite taking Donepezil. These findings suggest that taking 
Donepezil for six weeks did not improve HRV among persons taking the medication. 
There are however several methodological limitations to this study. Firstly, the time 
frame in which HRV was monitored (six weeks) is fairly short. As mentioned earlier, 
studies have indicated that cognitive improvement appears to take place after six weeks 
and continues to show therapeutic efficacy at six months (Rogers, 1998; Mohs, 2001). 
This suggests Donepezil requires at least six weeks in order to fully metabolize (Rogers, 
1998; Mohs et al., 2001). Secondly, participants were provided with a 3mg dose of 
Donepezil followed by a 5mg dose for six weeks. It is recommended that persons taking 
Donepezil start at a 5mg dose and titrate to a 10 mg dose (the therapeutic dose) after four 
to six weeks. Thirdly, participants HRV data was recorded using a 24-hour ECG while 
engaging in daily activities. This is problematic, as monitoring HRV while engaging in 
activities has been shown to cause variable oscillations in blood pressure creating 
interference or “noise” which may reduce accuracy (Gianfrance, Saul, Di Rienzo, & 
Mancia, 1994).  
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The present study will include participants who are taking both 5mg and 10mg 
doses of Donepezil as recommended by pharmacological studies (Feldman et al., 2001). 
Fourthly, respiration count was not factored into the HRV algorithm in this previous 
work. Obtaining a respiration count and incorporating this into the HRV algorithm is 
important for purposes of accuracy, particularly when measuring HF HRV 
(parasympathetic activity; Grossman & Taylor, 2006). Lastly, Masuda & Kawamura 
(2003) did not use normalized units (n.u.) when analyzing and reporting their HRV 
frequency data (LF, HF, and LF/HF). According to the Task Force on Heart Rate 
Variability (1996), measurement of LF and HF Power components are typically measured 
in absolute values of power (ms2) but LF and HF can also be measured in normalized 
units (n.u.). Using normalized units (n.u.) emphasizes changes in sympathetic and 
parasympathetic regulation by minimizing the effects of Very Low Frequency power. 
Normalized units display sympathetic and parasympathetic activity as a percentage, 
allowing the clinician to more easily gauge sympathetic versus parasympathetic 
dominance. The advantage of using normalized units surrounds the emphasis on the 
controlled and balanced behavior of the sympathetic and parasympathetic nervous 
system. Normalized units are also advantageous for tracking changes over time (e.g., 
when using a repeated measures design). Additionally, the normalization process 
expresses the quantities more easily by using percentage values (0%-100%). 
Normalization also reduces most of the large within and across-subject variability in the 
total raw HRV spectral power (Burr, 2007).  
The present study proposes the following three hypotheses: 1) participants that are 
diagnosed with mild to moderate AD and who are taking a stable dose of Donepezil 
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(Aricept®) will show increased parasympathetic nervous activity over a period of six 
months. This will be indicated by decreases in LF Power (n.u.) and LF/HF Ratio in the 
standing position at session 3 (six months) compared to session 1 (baseline). Thus, there 
will be a decrease in LF Power (n.u.) and LF/HF Ratio from session 1 (baseline) to 
session 3 (six months) when engaging in the orthostatic challenge (supine to standing). In 
contrast, HF Power (n.u.) and RMSSD will increase in the standing position at session 3 
(six months) compared to session 1 (baseline). Therefore, there will be an increase in HF 
Power (n.u.) and RMSSD from session 1 (baseline) to session 3 (six months) when 
engaging in the orthostatic challenge (supine to standing);  2) Healthy controls will show 
significant increases in HF Power (n.u.) from a supine to standing position at all three 
HRV recorded sessions (baseline, 3 months, and 6 months). The AD group will 
demonstrate minimal change in HF Power (n.u.) from a supine to a standing position at 
the baseline session, but will show increased HF Power (n.u.) from supine to standing at 
sessions 2 and 3. Changes in HF Power (n.u.) from a supine to a standing position at 
session 3 will be similar among both AD participants and healthy controls; and 3) 
Donepezil (Aricept®) will improve parasympathetic nervous activity through increased 
acetylcholine transmission, thus supporting the medication’s use as a potential protective 
agent against cardiac autonomic dysfunction.  
Currently, research examining cardiac cholinergic function among individuals 
with AD using Donepezil is limited. Implications of the current study include the 
potential utilization of Donepezil as a protective agent for those experiencing cardiac 
autonomic dysfunction. Early detection of parasympathetic depression among persons 
with AD and the prescription of Donepezil may help safeguard against a future cardiac 
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event such as bradycardia, arrhythmias, transient ischemic attack (TIA), myocardial 
infarct, or sudden death.  
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CHAPTER II  
LITERATURE REVIEW 
This chapter will outline research surrounding AD pathology, AD risk factors, 
cholinergic and cardiac autonomic function, the treatment efficacy of Donepezil 
(Aricept®), heart rate variability (HRV) and the significance of the presenting topic.   
Alzheimer’s Disease (AD) 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is 
characterized by neuropsychological, neuropsychiatric and neurological symptoms. AD is 
the most common cause of dementia and currently affects over five million US 
Americans aged 65 and older (Alzheimer’s Association, 2013; Center for Disease 
Control, 2013). By 2025, it is estimated that the number of people aged 65 and older with 
AD will reach a staggering 7.1 million. In 2012, caregivers provided approximately 17 
billion hours of unpaid care to persons with AD, and caregiver stress related to AD care 
is becoming increasingly problematic (Alzheimer’s Association, 2013). Typically, AD is 
diagnosed when the individual meets a set diagnostic criteria as provided by the 
American Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders Fifth Edition (DSM-5).  
According to the DSM-5, in order to make a diagnosis of AD, the individual must 
meet criteria for either a “minor” or “major” neurocognitive disorder (5th ed., DSM–5; 
American Psychiatric Association, 2013). A person who meets criteria for a major 
neurocognitive disorder must present with evidence of significant cognitive decline from 
a previous level of functioning in one or more of the following cognitive domains: 
13 
  
complex attention, executive functioning, learning and memory, language, perceptual-
motor, or social cognition (5th ed., DSM–5; American Psychiatric Association, 2013). 
This evidence must be based on the concern or knowledge of an informant, or there must 
be strong evidence of cognitive impairment as revealed by neuropsychological testing. 
The cognitive impairment must also interfere with the person’s ability to carry out 
activities of daily living (e.g., paying bills or managing medications), and cannot be the 
direct result of delirium or a severe mental illness (e.g., major depressive disorder). A 
diagnosis of mild neurocognitive disorder is assigned if the individual only exhibits mild 
to moderate cognitive decline in the same categories (5th ed., DSM-5; American 
Psychiatric Association, 2013).  
Once the criteria for a minor or major neurocognitive disorder has been satisfied, 
the individual must meet additional diagnostic criteria in order to be diagnosed with AD. 
The likelihood of this diagnosis as being “possible” or “probable” is also specified in 
accordance with accumulated evidence. The diagnostic criteria required to determine 
major and probable AD should include one or more of the following: an insidious or 
progressive onset, evidence of causative AD based on genetic evidence, clear evidence of 
memory decline, learning and decline in at least one other cognitive domain (as 
determined by neuropsychological testing), and a steady progressive or gradual decline in 
cognition. Finally, the change in cognition should not be the direct result of another 
condition such as cerebrovascular disease. A “possible” specifier is allocated if the 
evidence of AD is limited e.g., neuropsychological assessment data is absent but the 
patient displays AD features. A “probable” specifier is allocated if there is causative 
evidence of AD (e.g., as revealed by genetic testing). Lastly, mild AD is determined 
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based on similar criteria but the individual must display only mild to moderate symptoms 
(5th ed., DSM-5; American Psychiatric Association, 2013). A “possible” or “probable” 
specifier is assigned in a similar fashion as with major AD.  
AD is an insidious disease that presents with both positive and negative 
neuropathological features. These neuropathological features include both amyloid 
plaques and neurofibrillary tangles. These amyloid plaques (Aβ) and neurofibrillary 
tangles (NFT’s) were first described by Alois Alzheimer at the turn of the century 
following autopsies of a 51-year-old woman and 50-year-old man both of whom had 
dementia (Muir, 1996). The classic positive symptoms of AD include the presence of 
extracellular amyloid plaque deposits, neurofibrillary tangles (NFT’s), and neuropil 
threads (Nitsch, Slack, Wurtman, & Growdon, 1992; Serrano-Pozo, Frosch, Masliah & 
Hyman, 2011). Amyloid plaques are characterized by an accumulation of the amyloid-β 
peptide (Aβ) which is generated from the amyloid precursor protein (APP; Bertram & 
Tanzi, 2008). Neurofibrillary tangles in contrast, contain ribbon-like collections of tau 
proteins. Neuropil threads often accompany neurofibrillary tangles, and are thought to be 
the result of the breakdown of cell dendrites and axons that are constricted by the NFT’s. 
The topographic distribution of amyloid plaques originates in the basal areas of 
the frontal, temporal, and occipital lobe, but as the disease progresses, amyloid deposits 
can be found in the thalamus and hypothalamus (Braak & Braak, 1991). The distribution 
of NFT’s are more widespread than amyloid plaques, with the degeneration beginning in 
the allocortex of the medial temporal lobe, and later spreading to the isocortical region 
(Serrano-Pozo, Frosch, Masliah & Hyman, 2011). Neurodegenerative studies attribute the 
build-up of these plaques and tangles to the process of protein oligomarization. Protein 
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oligomarization occurs when certain neuronal proteins which are typically soluble (e.g., 
tau and α-synuclein), pathologically fold and oligomerize resulting in a type of protein 
meld (Selkoe, Mandelkow & Holtzman, 2012). This process of abnormal protein folding 
(or oligomarization) underscores the disease-like nature of AD.  
In contrast to the positive features of the disease, negative features primarily 
include neuronal and synaptic loss (Serrano-Pozo, Frosch, Masliah & Hyman, 2011). 
Neuronal loss is the main cause of cortical atrophy, and there are two main factors that 
result in neuronal death. Firstly, NFT’s occur within the neuron and displace the cell 
nucleus resulting in cell death. These tangle-bearing neurons (also known as “ghost 
tangles”) are identified by the appearance of a vacant nucleus. Secondly, neuronal death 
may occur as a result of apoptosis or programmed cell death (PCD) as a result of DNA 
fragmentation (Cotman & Su, 1996). Neuronal loss largely outnumbers NFT’s, thus 
neuronal loss has a much greater correlation with cognitive impairment. The cognitive 
impairment associated with AD is generally caused by neurodegeneration in the limbic 
system, neocortical regions, and the basal forebrain as well as synaptic and dendritic 
degeneration (Scheff, Price, Schmitt, & Mufson, 2005; Serrano-Pozo, Frosch, Masliah & 
Hyman, 2011). Research indicates a significant correlation between the number of 
synapses and cognitive function, with lower numbers of synapses resulting in poorer 
cognitive performance (Scheff, Price, Schmitt, & Mufson, 2005). Synaptic loss is a 
precursor to neuronal loss and is a main contributor to cortical atrophy. Synaptic loss 
disrupts the connections both within and between neurons, which is why synaptic density 
has the highest correlation with cognitive decline.  
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Aside from cognitive decline, individuals with AD present with deficiencies in 
numerous bodily functions. Cardiovascular disease (CVD) has been shown to correlate 
highly among persons with non-genetic AD. Non-genetic AD includes persons who 
present with AD pathology but lack the predisposing genetic traits commonly found in 
persons with the disease (e.g., Apolopoprotein E gene). A high percentage of individuals 
with AD present with cardiovascular conditions such as atherosclerosis, high blood 
pressure, hypertension, and coronary artery disease (De La Torre, 2002; Stewart, 1998).  
Epidemiological research suggests that CVD may directly contribute to AD pathology 
and more specifically, CVD may actually have a direct impact on AD pathology (De La 
Torre, 2002; Newman et al., 2005; Stewart, 1998). Conditions such as atherosclerosis 
have been shown to reduce cerebral blood flow to the brain (known as cerebral perfusion) 
resulting in impairment and white matter hyperintensity (De La Torre, 2002). 
Medications that improve cognitive function such as cholinesterase inhibitors (ChEls), 
also increase cerebral perfusion reinforcing the link between the cardiovascular system 
and neurocognitive functioning (De La Torre, 2002).  
Despite some of the distinct and unique differences in the symptomology of 
vascular dementia (VaD) and AD, there is also overlap with both clinical and 
pathological presentations. For example, individuals with VaD and AD both present with 
white matter changes, cerebral hypoprefusion (reduced cerebral blood flow), and genetic 
predispositions (De La Torre, 2002). The overlap in AD and VaD pathologies suggests 
that both diseases are influenced by similar processes. In addition to CVD, another bodily 
function which demonstrates decline as a result of AD pathology includes respiratory rate 
(Hrouova et al., 2012). Respiratory rate is controlled by the autonomic nervous system, 
17 
  
which is a subsystem of the peripheral nervous system. Autonomic nervous function is 
influenced and regulated by the neurotransmitter acetylcholine (ACh; Wessler, et al., 
2007). Therefore, decreases in respiratory rate may be the direct result of changes in 
cholinergic function and autonomic nervous function as a result of AD pathology. As 
indicated in this research, AD pathology appears to extend beyond the neurodegenerative 
symptoms commonly associated with the disease and cardiac autonomic function appears 
to play an important role in the disease. 
AD Risk Factors 
A large number of demonstrable risk factors have been shown to increase the 
etiology and likelihood of developing AD. Well-supported and correlated risk factors 
include: genetic vulnerability, cardiovascular disease (CVD), aging, ethnicity, physical 
inactivity, cognitive inactivity or low educational attainment, diabetes, midlife obesity, 
smoking, mild cognitive impairment, and ethnic background (Alzheimer’s Association, 
2013; Barnes & Yaffe, 2011; Kalaria et al., 2008).  
Genetics. The role of genetics in AD is heterogeneous and complex. Those who 
have a family member with AD are at greater risk for developing the disease 
(Alzheimer’s Association, 2013). AD that occurs before the age of 60 to 65 years of age 
is quite rare, and is referred to as autosomal dominant Alzheimer’s disease (ADAD) or 
early-onset AD. Early-onset AD is caused by mutations of three primary genes, all of 
which alter the production of amyloid-β (Aβ) peptide (Bertram & Tanzi, 2008). As 
previously mentioned, the production of Aβ is generated from the amyloid precursor 
protein (APP). The mutations associated with early-onset AD are located on the APP 
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gene or in the genes that are responsible for encoding proteins; these are presenilin 1 
(PSEN1) and presenilin 2 (PSEN2). The three primary genes involved in early-onset AD 
are referred to as deterministic genes, and almost guarantee that anyone with these 
specific gene mutations will develop the disease. Unlike early-onset AD, late-onset AD 
appears to develop from a multitude of risk alleles across different genes. These risk 
alleles are associated with the production, aggregation, and removal of Aβ peptide 
(Bertram & Tanzi, 2008). The gene most consistently linked to late-onset AD, is the 
Apolopoprotein E (apoE) gene (Blacker et al., 1997). The apoE gene contains four 
chromosomes, the fourth chromosome (apoE-4) of which is overrepresented in persons 
with late-onset AD. Although apoE-4 allele increases the risk of developing AD, only 20-
25% with inherent apoE-4 actually develop the disease suggesting that other factors are 
contributing to the etiology of the disease (Alzheimer’s Association, 2013).  
Cardiovascular Function. Research into the relationship between cardiovascular 
disease (CVD), AD, and cognitive decline is well established (Barnes & Yaffe, 2011; 
Newman et al., 2005; Stamper, 2006). Results from a cohort study of 4,971 older adults 
indicated that mean scores were lower on a test of general cognitive ability (Mini Mental 
State Examination) among individuals with a previous vascular event. Other factors that 
correlate with lower general cognitive ability scores include the presence of plaques in 
the carotid arteries and peripheral arterial atherosclerotic disease (PAD; Breteler, Claus, 
Diederick, Grobbee, & Hofman, 1994; Stampfer, 2006). Furthermore, research has 
indicated a higher prevalence of AD among those with clinical and subclinical coronary 
artery disease, raised systolic blood pressure, high serum cholesterol in mid-life, and 
hypertension (Barnes & Yaffe, 2011; Kivipelto et al., 2001; Newman, Ftizpatrick, & 
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Lopez, 2005). Autopsy studies have demonstrated a close relationship between the 
number of microvascular ischemic lesions as a result of cardiovascular incidents and 
Alzheimer lesions, indicating a probable interaction between the two (Stampfer, 2006). In 
corroboration with the above cardiovascular risk factors, Snowdon (2001) identified a 
34% prevalence rate of stroke among 118 nuns diagnosed with AD. This study was 
unique, because the nuns used in the study did not present with a history of negative 
lifestyle behaviors (such as alcohol use, drug use, or poor diet) therefore reducing the 
likelihood of confounding variables. Snowdon (2001) also demonstrated that older 
women required an eight fold increase of NFT’s to produce the same dementia severity as 
a person who has experienced a stroke, suggesting that dementia severity is mediated by 
cardiovascular incidents. It is also well established that certain ethnic groups present with 
a higher prevalence of both AD and CVD. For example, Latinos and African-Americans 
present with higher prevalence rates of AD compared to Caucasians, which coincides 
with a greater prevalence of CVD, metabolic syndromes (namely diabetes), high blood 
pressure, and high cholesterol (Alzheimer’s Association, 2013). Therefore there is a 
probable link between these two factors.  
Aging. Increased age is one of the most highly correlated risk factors associated 
with AD. The risk of developing AD doubles every five years after the age of 65 and 
after the age of 85 the risk increases to nearly 50% (Alzheimer’s Association, 2013). 
Exposure to deleterious conditions throughout life such as poverty, infectious diseases, 
malnutrition, and prenatal stress, may compromise healthy aging (Kalaria et al., 2008).  
Ethnicity. Research has indicated that HRV indices vary among different ethnic 
populations (e.g., African-American’s compared to European American’s). In particular, 
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African-American’s tend to generate higher levels of high frequency power and RMSSD 
and lower levels of low frequency power as compared to European Americans (Wang, 
Thayer, Treiber, & Snieder, 2005). This suggests that African-Americans have a 
propensity towards greater parasympathetic modulation and greater sympathovagal 
balance in comparison to European Americans. Therefore, it is important to consider 
these factors when evaluating HRV among different ethnic groups.     
Physical Inactivity. According to a meta-analysis of 16 prospective studies 
exploring physical inactivity and AD prevalence, approximately 1.1 million AD cases are 
potentially attributable to physical inactivity (Barnes & Yaffe, 2011). Individuals who 
engage in physical activity at least twice a week have 60% lower odds of developing AD 
and cognitive impairment compared to those who engage in frequent sedentary behavior 
(Barnes & Yaffe, 2011; Rolland, Kan & Vellas, 2008; Rovio et al., 2005). The effects of 
physical inactivity on cognitive decline are also more pronounced among individuals that 
carry the apoE-4 gene, suggesting that physical activity may somehow modify the 
development of apoE-4 gene mutations (Rovio et al., 2005). Reductions in cognitive 
decline among persons who exercise regularly are likely to be related to the 
cardiovascular benefits of physical activity. Physical activity mitigates conditions that 
increase the risk of developing dementia such as hypertension, hypercholesterolemia, 
diabetes mellitus, and obesity (Rovio et al., 2005).   
Cognitive Inactivity & Low Educational Attainment. Both cognitive inactivity 
and shorter years of education pose as risk factors for AD pathology (Barnes & Yaffe, 
2011; Hall, Sujuan, Frederick & Hendrie, 2000). Individuals with higher levels of 
education (more years in education) and higher occupational attainment show less 
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clinical signs of memory loss when compared to those with lower educational and 
occupational attainment (Attix & Welsh-Bohmer, 2006). However, research findings 
suggest that persons with higher educational attainment are better able to find ways to 
compensate for memory decline using compensatory strategies (also known as cognitive 
reserve). Those with higher cognitive reserve tend to show a slower decline in memory 
function at the early stage of the disease, but experience more rapid/stepwise progression 
when global functions become impaired (Reed, et al., 2010; Scarmeas, Albert, Manly & 
Stern, 2006).  
Obesity. Longitudinal epidemiological meta-analyses demonstrate higher rates of 
AD among persons with a history of obesity (Barnes & Yaffe, 2011; Profenno, 
Porsteinsson, & Farone, 2010). In particular, high body mass index (BMI) is associated 
with an increased risk of all-cause dementia. According to the National Heart, Lung, and 
Blood Institute (2014), a normal BMI is considered to be between 18.5 (kg) and 24.9 (kg) 
while a BMI of 30 (kg) or greater is considered overweight. It is thought that obesity may 
exacerbate the causal mechanisms involved in the development of the disease via a 
genetic interaction. Those with a higher BMI present with a greater prevalence of the fat 
mass and obesity associated gene or the FTO polymorphism (Keller, Xu, Wang, Winbald, 
Fratiglioni, & Graff, 2010). An interaction seems to exist between the FTO gene and the 
apoE-4 gene, and those carrying the FTO gene appear to have a greater expression of the 
apoE-4 gene resulting in a greater risk of AD. The effects of obesity have been shown to 
coincide with the increased risk of developing CVD and metabolic syndromes such as 
diabetes, both of which significantly increase AD risk (Profenno, Porsteinsson, & Farone, 
2010; Sharma, 2003). Individuals who present with both diabetes and an apoE-4 allele, 
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have approximately double the risk of developing the disease in comparison to those who 
possess neither (Messier, 2003). Overall, obesity appears to be a risk factor for AD due to 
its negative impact on the cardiovascular system.   
Smoking. Smoking furthers the risk of developing AD particularly among those 
who carry the apoE-4 gene (Barnes & Yaffe, 2011; Ott et al., 1998; Rusanen et al., 2010). 
Smoking is a heavy detriment to the cardiovascular system, often resulting in a higher 
risk of a myocardial infarct (MI), coronary artery disease (CAD), carotid wall thickening, 
and internal carotid stenosis (Ambrose & Rajat, 2004; Tell et al., 1994).  
Mild Cognitive Impairment. Mild cognitive impairment (MCI) is a prodromal 
state of cognitive function that falls between the changes seen in healthy aging and 
meeting criteria for dementia (Peterson, 2011; Kalaria et al., 2008). MCI is classified into 
two subtypes; amnestic and non-amnestic mild cognitive impairment. Amnestic MCI 
primarily affects memory function, and persons with amnestic MCI often present with 
increasing forgetfulness but other functions are spared (e.g., executive functioning). The 
capacities affected by non-amnestic MCI generally include executive and visuospatial 
function with memory largely remaining intact. The prevalence of MCI among those 
aged 65 years and older is approximately 10-20%. The rate in which those diagnosed 
with MCI who eventually go on to develop AD is approximately 5-10% in community 
samples and 10-15% in clinical samples (Peterson, 2011). Individuals who present with 
the apoE-4 gene, a hippocampal volume below the 25th percentile, and elevated levels of 
cerebral spinal fluid (CSF) tau protein, are at greater risk of developing AD after being 
diagnosed with MCI.  
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Overall, there are numerous factors that exacerbate the risk of developing AD. 
Although individual factors pose an increased risk, combinations of risk factors such as 
the apoE-4 genotype and high BMI seem to drastically increase the risk of developing the 
disease above and beyond individual factors. Two of the greatest risk factors for AD 
include a genetic predisposition and CVD. These risk factors are then mediated by 
negative lifestyle behaviors such as physical inactivity, and alcohol and tobacco use. The 
relationship between CVD and negative lifestyle behaviors may also be bi-directional, 
with negative lifestyle behaviors increasing the likelihood of developing CVD. Therefore, 
it is the interaction of multiple risk factors that may increase the overall risk of a person 
developing AD.  
Cholinergic Function and Cardiac Autonomic Function 
In addition to the positive and negative symptoms present in the AD brain, 
changes in the neurotransmitter system also occur in persons with the disease. The 
neurotransmitter acetylcholine (ACh) plays a primary role in neurocognitive function 
(mainly learning and memory) and cardiac autonomic function. Cholinergic resources 
become increasingly deficient in the AD brain resulting in neurocognitive impairment 
and cardiac autonomic dysfunction (Bartus, 1999; De Vilhena & Fernando, 2009; 
Feldman, 2001; Schliebs & Arendt, 2006). Decreases in choline acetyl transferase 
(ChAT), a biochemical marker for cholinergic neurons, are found in the brain of AD 
patients (Muir, 1996). Reductions in levels of ACh are caused by the loss of presynaptic 
neuronal structures (e.g., ChAT) in the basal forebrain. A landmark study by Perry, 
Tomlinson, Blessed, Bergman, & Gibson et al (1978) demonstrated a strong correlation 
between cholinergic neuronal loss identified via autopsy and decreased mental state 
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examination scores (Muir, 1996). These findings along with others were significant in the 
development of the “cholinergic hypothesis”, which theorized a link between cholinergic 
resource depletion in the central nervous system and decreased cognitive function 
(Bartus, 1999). The cholinergic hypothesis in comparison to a number of other theories 
pertaining to the neurodegenerative pattern in AD, has produced strong evidence of 
efficacy in well controlled, multicenter trials (Muir, 1996). Early studies showed support 
for the theory when the symptoms of memory loss seen in the AD presentation were 
replicated by blocking cholinergic receptors in young adults (Schliebs & Arendt, 2006). 
More recent studies have provided supporting evidence for the hypothesis using in-vivo 
measurements of cholinergic receptor expression via positron emission tomography 
(PET) technology (Schliebs & Arendt, 2006). Additionally, researchers Toledo & 
Junqueira (2009) explored correlations between MMSE scores from AD participants and 
HRV indices. Results from this study indicated that cognitive deficiency was correlated 
with lower cardiac parasympathetic modulation and a trend for higher cardiac 
sympathetic modulation. 
Cholinergic neurons can be subdivided into two categories: projection neurons 
and interneurons. Projection neurons are primarily concentrated in the forebrain and 
upper brain stem, whereas interneurons are located in the caudate-putamen (cerebral 
cortex), nucleus accumbens (basal forebrain), hippocampus, cerebral cortex, 
hypothalamus, and spinal cord (Schliebs & Arendt, 2006). Most importantly, cholinergic 
projection neurons also comprise of motor neurons in the spinal cord and cholinergic 
neurons in the sympathetic (SNS) and parasympathetic nervous system (PNS). 
Cholinergic function is involved in controlling cerebral blood flow, cortical activity, the 
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sleep-wake cycle, and modulating cognitive function (Schliebs & Arendt, 2006). 
Cholinergic function is a primary regulatory neurotransmitter of the autonomic nervous 
system (ANS). The autonomic nervous system regulates both the sympathetic and 
parasympathetic nervous system, and is involved in cardiac regulation as well as 
respiration (Task Force on Heart Rate Variability, 1996).  
For more than 40 years, AD has been classified as a genetic neurodegenerative 
disorder but epidemiological studies indicate that AD may also be non-genetic and 
initiated by vascular factors that precede the neurodegenerative process (De La Torre, 
2002). Cardiac autonomic dysfunction is prevalent among individuals with AD, and this 
generally reflects an increase in sympathetic activity and a decrease in parasympathetic 
activity (or parasympathetic depression; Toledo & Junqueira, 2009). This could be a 
direct result of cholinergic dysfunction, and it is well established that persons with AD 
generally present with depleted cholinergic resources in tandem with autonomic 
dysfunction indicating a probable link between the two. Examples of autonomic 
dysfunction among those with AD can include increased cardiovascular mortality, higher 
risk of arrhythmias, sudden death, and other cardiac events (Allan et al., 2007; Kleiger, 
Miller, Bigger, & Moss, 1986). A relationship between higher cognitive function and 
autonomic function has been demonstrated which could be mediated by cholinergic 
function (Critchley, 2005; Hugdahl, 1996; Royall et al., 2006). Therefore, it is possible 
that cardiac autonomic dysfunction may represent a decrease in cholinergic resources as 
well as increased cardiovascular risk. 
In contrast to the evidence indicating a direct and causal link between cardiac 
autonomic dysfunction and AD (or vice-versa), other studies have indicated a parallel 
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process whereby AD and cardiac autonomic dysfunction co-occur. For example, the 
existence of cardiac autonomic dysfunction (e.g., cerebrovascular disease) may lead to 
deep white matter infarction and subsequent white matter disease (WMD; Andin, 
Passant, Gustafson, & Englund, 2006). White matter disease correlates highly with AD 
and cerebral amyloid angiopathy (CAA). CAA is the build-up of amyloid plaques within 
the walls of brain arteries, and these plaques are similar to the Aβ plaques found in the 
AD brain. As vascular complications progress (e.g., atherosclerosis and CAA), the 
severity of AD tends to progress in a similar fashion (Andin, Passant, Gustafson, & 
Englund, 2006; De La Torre, 2002). 
In corroboration with the evidence surrounding a parallel process, cardiovascular 
conditions have been shown to cause reduced cerebral perfusion (cerebral blood flow) or 
hypoperfusion as well as cognitive impairment (Toledo Ferraz Alves, Ferreira, 
Wajngarten, & Busatto, 2010). This hypoperfusion pushes oxidative stress towards the 
brain resulting in cognitive decline (De La Torre, 2002). Hypoperfusion is likely a 
precursor to AD pathology but may also mediate AD symptomology. It is also well-
known that Aβ and NFT’s have been found in the brains of healthy older adults who 
show no signs of AD (De La Torre, 2002). As mentioned previously, Snowdon (2001) 
demonstrated that older women required an eight fold increase of NFT’s to produce the 
same dementia severity as a person who has experienced a stroke, suggesting that 
dementia severity is mediated by cardiovascular health. This could indicate that a parallel 
process involving both cardiovascular and neurocognitive systems is necessary to induce 
AD pathology.  
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Donepezil 
The medication Donepezil hydrochloride (Aricept®) is a popular ChEls used to 
treat cognitive impairment among persons with AD. Donepezil is a highly selective 
ChEls designed to prevent and slow the progression of cholinergic deficiency which 
greatly impacts neurocognitive function (Feldman et al., 2001; Bartus, 1999). ChEls 
operate by blocking the acetylcholine esterase (AChE) and butylcholinesterase (BuChE) 
enzymes which typically hydrolyze acetylcholine (Rogers, 1998). The recommended 
dose for persons taking Donepezil is 5mg over a period of four to six weeks which is then 
titrated to the therapeutic dose of 10mg if the medication is well tolerated (Feldman et al., 
2001; Mohs et al., 2001). Results from a number of placebo-controlled studies looking at 
the effects of Donepezil on cognitive function have indicated significant reductions in the 
rate of cognitive decline (neurodegeneration) and mild cognitive gains in persons with 
mild to moderate AD who are taking the medication (Mohs et al., 2001; Rogers et al., 
1998; Feldman et al., 2001). This reduction in cognitive decline and improvement in 
cognitive functioning during Donepezil treatment appears to be evident after six weeks of 
taking the medication (Mohs et al., 2001; Rogers, 1998) but greater gains can be seen at 
six months (Mohs et al., 2001). Additional findings suggest that Donepezil may also help 
reduce cognitive decline among persons with more progressive and severe stages of the 
disease (Feldman, 2001).  
 Although Donepezil may slow the rate of cognitive decline, the medication and 
other ChEls have been shown to cause uncommon side effects such as dizziness and 
syncope, bradycardia (abnormally slowed heart rate), atrial arrhythmias, myocardial 
infarction, angina, seizures, atrioventricular block, and orthostatic hypotension (Bordier, 
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2006; Calvo-Romero & Ramos-Salado, 1999; Newby, Kenny, & McKeith, 2006; 
Rowland, Rigby, Harper, & Rowland, 2007). These adverse effects are however mostly 
seen in cases where the amount of Donepezil metabolized has greatly exceeded the 
therapeutic dose, but some have reported mild side-effects from the recommended dose 
(Bordier et al., 2005). The prevalence of bradycardia as a result of taking Donepezil is 
rare with the base rate being around 1% (Bordier et al., 2005; Rowland, Rigby, Harper, & 
Rowland, 2007). It is important to mention that bradycardia is fairly common among the 
general population (all ages), with approximately 15% of males and 2% of females 
meeting criteria for clinically defined bradycardia (Ostchega, Porter, Hughes, & Dillon, 
2011). Thus, the percentage of individuals developing bradycardia as a result of taking 
Donepezil is quite low in comparison to the general base rate. The frequency of adverse 
events such as dizziness and syncope are more common, and are reported in around 1-
10% of persons taking the medication (Rowland, Rigby, Harper, & Rowland, 2007). 
Atrioventricular block is exceptionally rare, and occurs in 0.001-0.1% of those taking the 
medication.. It is hypothesized that side-effects such as bradycardia and arrhythmia are 
triggered by increased acetylcholine production or increased vagal neurotransmission 
which acts to slow heart rate. However, Donepezil has also been shown to improve 
cardiac autonomic dysfunction by increasing heart rate variability (HRV) among persons 
with AD as well as animal subjects (Giubilei et al., 1998; Umegaki & Khookhor, 2013). 
Limitations to these studies include measuring changes in HRV at a single (and varied) 
time frame (12 weeks ± 4 weeks), using a now discontinued ChEI, measuring changes in 
HRV over a short time frame (2 weeks), the absence of normalized units when 
identifying changes in HRV over time (Masuda & Kawamura, 2003; Umegaki & 
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Khookhor, 2013), using animal subjects (rats), and the lack of a healthy control group 
(Da Costa Dias et al., 2013; Giubilei et al., 1998; Umegaki & Khookhor, 2013).  
Previous research has also explored the medium term effects of cholinesterase 
inhibitors on cardiac health. For example, researchers Nordstrom et al (2013) studied the 
prevalence of myocardial infarcts (MI) and rate of death among individuals with AD who 
were taking a cholinesterase inhibitor (N= 7,073) over a period of five years. Results 
from the study found that participants who used ChEls had a 34% lower risk of 
experiencing an MI. Cholinesterase inhibitor use was also associated with a lower risk of 
death. Therefore, Donepezil may present with cardio-protective properties in addition to 
improving neurocognitive function. These positive side-effects of the medication 
Donepezil are likely the result of changes in cardiac autonomic function as a result of 
increased ACh production.  
Heart Rate Variability (HRV) 
Over the past 25 years, there has been an increased recognition in the relationship 
between the autonomic nervous system (ANS) and cardiovascular mortality (Task Force 
on Heart Rate Variability, 1996). Following the recognition of ANS markers and the 
consequences of autonomic dysfunction, interest in obtaining heart rate variability (HRV) 
measures via electrocardiogram (ECG) have grown significantly (Balocchi et al., 2006). 
Epidemiological and clinical data using ECG technology indicate autonomic and 
neuroanatomic dysfunction in persons with AD, and more specifically parasympathetic 
depression (Bartus, 1999; Giubilei et al., 1998; Toledo & Junqueira, 2008, 2009; Zullii et 
al., 2005). Heart rate and heart rhythm are primarily controlled by the autonomic nervous 
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system (ANS), which comprises of two distinct subsystems; the sympathetic nervous 
system (SNS) and the parasympathetic nervous system (PNS). The SNS and PNS work in 
complementary and opposing ways. The PNS influences heart rate by the release of ACh 
neurotransmission via the vagus nerve. The release of ACh results in diastolic 
depolarization which causes heart rate activity to slow (Task Force on Heart Rate 
Variability, 1996). Reductions in PNS activity is often referred to as vagal withdrawal, 
and is indicative of impaired autonomic function. Neurotransmitters including the release 
of epinephrine and norepinephrine, activate adrenergic (adrenaline) receptors causing an 
increased SNS response and slowed diastolic depolarization.  
Heart rate variability is monitored using ECG technology which provides an 
algorithm of SNS and PNS activity. Assessment of SNS and PNS activity can be 
obtained via spectral analysis of HRV which provides both low frequency (LF) and high 
frequency (HF) cardiovascular output. Increased vagal afferent excitation results in vagal 
efferent activity (PNS) which (in turn) inhibits the sympathetic nervous response. 
Efferent vagal activity is of high interest here, because it can be measured by HF HRV 
output from an electrocardiogram (ECG) thus providing a quantitative measure of PNS 
activity. The simplest measurement of HRV is the time domain method, which utilizes 
the individual’s heart rate at a certain point in time and the intervals between successive 
normal complexes (also known as RR interval variability; Task Force on Heart Rate 
Variability, 1996). The time domain method can be used to capture both short-term (e.g., 
5-7 minutes) or long-term recordings (e.g., 24 hour period). Due to the nature of this 
study, short-term recordings will be obtained over a period of six minutes in two different 
positions (supine and standing). Short-term recordings (5 minute intervals) have been 
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used in previous studies to accurately capture HRV data in persons with AD (Allan et al., 
2006; Giubilei et al., 1998; Siepmann et al., 2006; Toledo & Junqueira, 2008). The most 
commonly used time-domain measures include the mean squared differences of 
successive R-R intervals (RMSSD). This is used as a measurement to estimate the high 
frequency variations in heart rate.  
Using short-term recordings, the following spectral components can be derived 
from the HRV algorithm; low frequency (LF), high frequency (HF) and LF/HF ratio. The 
proportional variations of LF and HF output are represented by the LF/HF ratio. The 
spectral components are available in both absolute values (ms2) or normalized units (n.u.) 
and represent changes in autonomic heart function. The advantage of using normalized 
units surrounds the emphasis on the controlled and balanced behavior of the sympathetic 
and parasympathetic nervous system (Task Force on Heart Rate Variability, 1996). Using 
normalized units (n.u.) emphasizes changes in sympathetic and parasympathetic 
regulation by minimizing the effects of Very Low Frequency power. The Task Force on 
Heart Rate Variability (1996) state that power in normalized units (n.u.) should always be 
reported with absolute values of LF and HF Power in order to describe in total the 
distribution of power in the spectral components. Normalized units are also advantageous 
for tracking changes over time (e.g., when using a repeated measures design) and are 
similar to a standard score. In addition to this, the normalization process expresses the 
quantities more easily by using percentage values (0%-100%). Normalization also 
reduces most of the large within and across-subject variability in the total raw HRV 
spectral power as well (Burr, 2007).  
32 
  
With regards to standardized HRV data using normalized units, a meta-analysis of 
44 publications exploring short-term HRV among healthy adults (≥ 18 years) suggests 
that mean normal values of low frequency power (expressed in normalized units) should 
be approximately 52% (SD= 10), while mean normal values of high frequency power 
(expressed in normalized units) should be approximately 40% (SD= 10; Nunan, 
Sandercock, & Brodie, 2010). Additionally, mean normal values of RMSSD should be 
approximately 42 (ms; SD= 15) while the mean normal value of the LF/HF Ratio should 
be approximately 2.8 (SD= 2.6; Nunan, Sandercock, & Brodie, 2010). It is important to 
mention that the mean values generated from this study were based on HRV data 
obtained in a range of positions (e.g., supine, standing, resting etc.) and from individuals 
of varying ages (≥18).  
Previous studies have explored frequency domain analysis using LF, HF, and 
LF/HF ratio indices to determine cardiac autonomic change among those with AD versus 
healthy controls (Allan et al., 2007; Da Costa Dias, et al., 2013; Giubilei et al., 1998; 
Masuda & Kawamura, 2003; Toledo & Junqueira, 2009). Using a cross-sectional design, 
researchers Toledo & Junqueira (2008) studied cardiac autonomic function and cognitive 
function in 22 participants with probable AD (Mean age = 79.6) and compared them to 
24 healthy participants (Mean age= 68.6). Cardiac autonomic function was measured 
during five minute HRV intervals and frequency domain indexes in both supine and 
standing positions. The HRV analysis was performed according to the methodological 
standards recommended by the Task Force on Heart Rate Variability (1996). Each 
individual completed a five minute series of R-R intervals in both supine and standing 
positions using digital ECG technology and compatible software. Both time-domain and 
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frequency-domain analyses were conducted (Toledo & Junqueira, 2008). Cardiac 
sympathetic and parasympathetic modulation was measured using a time-domain 
analysis, a mean R-R interval series and two variability indices. This included the 
standard deviation of intervals (SDNN) and the coefficient of variation (SDNN/mean). 
Two separate indices were also used and included the percentage of successive adjacent 
R-R intervals greater than 50 ms (pNN50%), and the square root of the mean successive 
differences between adjacent R-R intervals (RMSSD; Task Force on Heart Rate 
Variability, 1996). These reflect the rapid beat-to-beat shifts in intervals that are derived 
from the parasympathetic modulation associated with respiration (Toledo & Junqueira, 
2008). 
Frequency domain analyses were also conducted by the authors, which provided a 
functional measure of HRV frequency distribution. These frequencies included very low 
frequency (0–0.04 Hz), low frequency (0.04–0.15 Hz), and high frequency (0.15–0.50 
Hz) spectral bands. The frequency domain measures include total power spectral area, 
which demonstrates the level of the overall autonomic modulation. Low frequency bands 
are a measure of SNS activity while high frequency bands are an indication of PNS 
activity (Task Force on Heart Rate Variability, 1996). The ratio of the low to high 
frequency indices (LF/HF ratio) provides an estimative of the sympathovagal balance. If 
the LF/HF ratio is less than 1, then this indicates a dominance of parasympathetic 
modulation whereas if the ratio is greater than 1, this is indicative of sympathetic 
dominance (Toledo & Junqueira, 2008). The mean and frequency domain indices in each 
group were compared using Student t-tests. Multiple logistic regression analyses were 
conducted to verify if the HRV indices were affected by independent confounding 
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variables (e.g., caffeine use, blood pressure, and alcohol use). Logistic regression 
analyses revealed changes in sympathovagal balance, which was altered towards 
parasympathetic depression and sympathetic exacerbation in both the supine and standing 
posture among persons with AD (Toledo & Junqueira, 2008).  
Supporting evidence for reductions in HRV were identified in similar studies by 
Zulli et al (2008) and Allan et al (2007). Zulli et al (2008) compared HRV markers of 33 
participants with AD and 29 participants with MCI to healthy controls using 24-hour 
ECG monitoring. The researchers also monitored blood pressure changes over a 24-hour 
period, and controlled for various lifestyle behaviors including smoking habits and 
hypertension. High and low blood pressure have been linked to changes in cardiac 
autonomic function, which is why this factor was a potential confound (Acharya, et al., 
2006; Pavithran, Prakash, Dutta, & Madanmohan, 2010). Persons with a history of heart 
failure, coronary artery disease, diabetes mellitus, or severe clinical conditions (e.g., 
cerebrovascular disorders) were excluded from the study. Student t-tests were conducted 
to detect changes in continuous variables, and categorical variables were analyzed using a 
chi-square analysis. The authors then used a Pearson linear correlation analysis to 
evaluate the correlation between HRV and cognitive impairment. Results indicated that 
HRV time and frequency domain parameters were lower in patients with AD in 
comparison to patients with MCI and healthy controls (Zulli et al., 2008). More 
specifically, the AD group showed much lower high frequency output compared to 
healthy controls. Allan et al (2007) compared HRV among persons with AD, VaD, and 
Lewy Body Dementia (LBD) using ECG technology. Results further indicated decreased 
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PNS activity among individuals with all types of dementia suggesting that decreased 
autonomic dysfunction is not unique to dementia of the AD type.  
Currently, there are only a few studies exploring the cardio-protective benefits of 
ChEl treatment among individuals diagnosed with AD. One of these studies was 
conducted by researchers Giubilei et al (1998). In this study, authors Giubilei et al (1998) 
explored cardiac autonomic function in persons with probable AD (n= 12) versus healthy 
controls (n= 12). The AD group were receiving ChEl treatment for one month using a 
now discontinued medication named eptastigmine. Before the participants received 
eptastigmine, a recording of the HRV was performed during a head-up tilt test. This was 
then repeated on the last day of treatment. The same frequency bands used in the Toledo 
& Junqueira (2008) study were used in this study (HF, LF, and LF/HF ratio). Results 
indicated that before treatment, HF Power (parasympathetic function) was lower in AD 
participants compared to healthy controls while in the resting position. Following one 
month of ChEl treatment, AD participants showed a similar magnitude of HF Power in 
the resting position compared to healthy controls. Additionally, AD participants showed 
similar patterns of HRV output following ChEl treatment when placed in the tilting 
position compared to healthy controls. Overall, both groups showed similar increases in 
the magnitude of LF Power and decreased HF Power when placed in the tilting position. 
The authors concluded that cardiac autonomic dysfunction may be present in persons 
with AD as a result of a cholinergic deficit in the peripheral autonomic nervous system. 
However, this cardiac autonomic dysfunction can be normalized by ChEl treatment 
(Giubilei et al.,1998). A major limitation to this study includes the use of a now 
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discontinued ChEls and the short time frame in which pre/post measures were obtained 
(one month).  
Another study conducted by Masuda & Kawamura (2003) explored the effects of 
the more modern and widely used cholinesterase inhibitor Donepezil hydrochloride 
(Aricept®). The authors examined the effects of Donepezil on autonomic nervous 
activity among 17 participants with a diagnosis of probable AD. The severity of AD was 
controlled for in the analysis by quantifying dementia severity using a dementia screening 
tool. Using 24-hour ECG technology, Masuda & Kawamura (2003) obtained HRV before 
the participants began taking Donepezil and six weeks after the participants started 
Donepezil. Participants were however initially administered a 3mg dose of Donepezil in 
the morning for 2 weeks as a running-in period and after these 2 weeks, the dosage was 
increased to 5mg per day where it remained. HRV was measured using frequency domain 
analyses over a 24-hour period. Results indicated that low frequency and high frequency 
components were significantly reduced with treatment and ultralow and very low 
frequency components were not affected. The reduction in the high frequency 
(cholinergic) component was also greater than the reduction in the low frequency 
component, indicating a greater decrease in parasympathetic (cholinergic) activity in 
comparison to sympathetic activity over the period of six weeks. Results from this study 
indicate that Donepezil reduced parasympathetic activity and cholinergic function among 
those taking Donepezil, which contradicts the findings from Giubilei et al (1998) and 
Umegaki & Khookhor (2013).  
Similar findings to the Masuda & Kawamura (2003) study were also obtained by 
Siepmann et al (2006) and McLaren et al (2003). Siepmann et al (2006) explored the 
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effects of Donepezil treatment on RMSSD among individuals diagnosed with AD while 
in the resting position. RMSSD was captured using HRV technology at a single time 
frame. The duration in which ChEl treatment was administered was not specified. The 
authors also used an AD control group who were not being treated with Donepezil. 
Results indicated a lower magnitude of RMSSD (parasympathetic nervous activity) 
among the AD group during Donepezil treatment versus the AD (non-ChEl treatment) 
control group. Major limitations to this study include the use of a single time frame to 
capture HRV, the absence of normalized units, as well as the unspecified length of time 
in which individuals with AD were taking the medication Donepezil. Additionally, 
researchers McLaren et al (2003) explored the effects of Donepezil on HRV among 
individuals diagnosed with AD and Lewy Body Dementia before and after ChEl 
treatment. HRV was obtained through the use of a five minute HRV analysis. Results 
indicated that HRV was significantly reduced following treatment with Donepezil as 
indicated by reductions in high frequency power. Limitations to this study include the use 
of a single time frame, absence of a control group, and absence of normalized units. The 
researchers of both studies did not account for various confounding factors (e.g., physical 
activity, caffeine use, gender) which have been shown to influence HRV.  
A more recent study conducted by researchers Umegaki & Khookhor (2013), 
explored the effects of Donepezil (3mg) on HRV using animal (rats) subjects. The 
authors administered Donepezil to 32 rats and monitored their low frequency (LF), high 
frequency (HF) and the LF/HF Ratio indices over a period of two weeks. The rats HRV 
was obtained on the day the initial dose was ingested and at one and two weeks after the 
initial dose was ingested. On day one, authors found an increase in sympathetic nervous 
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activity as evidenced by LF dominance (LF/HF Ratio). However, at weeks one and two, 
the magnitude of the LF output had decreased significantly and HF dominance was 
apparent. The authors concluded that initially ChEl treatment induced sympathetic 
nervous activation acutely, but longer-term ingestion (two weeks) induced 
parasympathetic activation. Additionally, another recent study exploring the effects of 
ChEl treatment on HRV and blood pressure, identified improvements in cardiac 
autonomic balance and diastolic and systolic blood pressure following ChEl treatment 
(Da Costa Dias, et al., 2013). In older adults, increasing blood pressure produces cardiac 
slowing as a result of reductions in baroreceptor reflex sensitivity (Simpson & Wicks, 
1988). The baroreceptor reflex is a strong reflex of the brainstem and baroreceptors are 
located in the auricles of the heart and vena cavaeis (Berntson, 1997). The baroreceptor 
reflex is involved in maintaining blood pressure and homeostasis. More specifically, if 
blood pressure decreases the baroreceptor reflexes act to help restore blood pressure by 
increasing heart rate. Baroreceptor reflexes exert powerful inhibitory influences on 
sympathetic outflow and also stimulate vagal (ANS) activity (Berntson, 1997). As such, 
older adults have the tendency to demonstrate poorer HRV with age but disease 
pathology (e.g., dementia) causes larger decreases in HRV (Toledo & Junqueira, 2008). 
The study by Da Costa Dias et al (2013) may suggest that decreases in high blood 
pressure as a result of improved baroreceptor reflex sensitivity may in turn, improve heart 
rate variability. Previous research has also indicated a strong relation between high blood 
pressure and greater LF Power (sympathetic exacerbation) among hypertensive 
participants versus healthy controls (Piccirillo, Munizzi, Fimognari, & Marigliano., 
39 
  
1996). Therefore, LF Power is thought to reflect baroreceptor-mediated regulation of 
blood pressure (Bernston, et al., 1997; Friedman & Thayer, 1998). 
Respiratory Sinus Arrhythmia (RSA) 
In order to improve the accuracy of measuring parasympathetic activity via high 
frequency HRV, respiration count is often incorporated into the HRV algorithm. This 
measure is known as the respiratory sinus arrhythmia or RSA (Grossman & Taylor, 
2006).  The respiratory sinus arrhythmia is attributed to parasympathetic activity, and is 
frequently utilized as an index of cardiac vagal tone (Grossman & Taylor, 2006). Cardiac 
vagal tone is a process by which the vagus nerve controls and regulates the 
parasympathetic nervous system and is responsible for homeostatic regulation. Heart rate 
has been shown to synchronize with respiratory rhythm, and the R-R interval on an ECG 
is shortened during inspiration and prolonged during expiration (Yasuma & Hayano, 
2004). Therefore, obtaining respiratory parameters can be advantageous in providing a 
more accurate measure of parasympathetic activity. 
HRV Positioning 
Research has demonstrated that HRV, diastolic and systolic blood pressure (BP), 
high and low frequency band power of HRV all show significant changes when 
positioning is altered from a supine to a standing posture (Acharya, et al., 2006; 
American Heart Association, 1996; Aysin & Aysin, 2007). The orthostatic challenge 
(supine to standing) is also one of the most common tests to detect cardiac autonomic 
dysfunction (Aysin & Aysin, 2007). Physical activity has also been shown to cause 
oscillations in blood pressure creating interference or “noise” with HRV measures 
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(Gianfrance, Saul, Di Rienzo, & Mancia, 1994). Obtaining HRV readings from a still 
resting position to a standing position will help identify any significant changes in SNS 
and PNS activity. Toledo & Jaunqueira (2008) demonstrated large differences in high 
frequency (HF) bands among persons in both supine (M= 28.0 ms2) and standing (M= 
13.8 ms2) positions, which is consistent with previous research (Fagard, 2001). The heart 
rate response to standing evaluates the cardiovascular response initiated by a change from 
horizontal to a vertical position. The typical heart rate response to standing (increased 
sympathetic activity) is largely mitigated by parasympathetic activity (Risk, Broadbridge, 
& Cohen, 2001). In healthy individuals, there is a characteristic and rapid response to 
standing which is followed by a relaxation bradycardia (Risk, Broadbridge, & Cohen, 
2001). Research has shown that shifts in positioning (e.g., a head tilt or sit to stand) 
among persons with AD and healthy older adults can alter HRV (Toledo & Junqueira, 
2008). The present study will use both supine and standing positions to measure HRV. 
Using a still resting position will also decrease the likelihood of additional frequency 
interference (Gianfrance, Saul, Di Rienzo, & Mancia, 1994). It is recommended that the 
participant should be in a resting position prior to commencing the standing 
measurement. So far, the results of the few studies examining cardiac autonomic function 
in AD present with varying results in frequency-domains. This is likely the result of 
varying methods of measuring heart rate variability such as using a stand versus a supine 
position or a 24-hour ECG (Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann 
et al., 2006; Toledo & Junqueira, 2008).  
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HRV Confounds 
When assessing HRV in the present study, it will be important to identify factors 
that may influence cardiac autonomic function as these factors could undermine the 
validity of the HRV analysis. It is well known that persons who present with severe 
coronary artery disease, congestive heart failure, atherosclerosis, high blood pressure, or 
stroke present with decreased heart rate variability (Kleiger, Miller, Bigger, & Moss, 
1986; Kwon et al., 2008; Naver, Bloomstrand, & Wallin, 1996). More specifically, 
measures of high frequency HRV appear to be significantly lower among persons with 
cardiovascular disease indicating decreased parasympathetic nervous response (or vagal 
withdrawal; Evrengul et al., 2006). Therefore, it will be important to exclude individuals 
with severe cardiac conditions such as a history of stroke from the study, and control for 
more mild cardiac conditions (e.g., high blood pressure) in the analyses. 
Frequent exercise (two to three times per week) has also been shown to increase 
heart rate variability as demonstrated by increases in high frequency HRV among young 
and older adults (Sandercock, Bromley, & Brodie, 2005; Schuit et al., 1999). Therefore, it 
will be necessary to document the amount of hourly exercise each participant engages in 
per week as this could potentially inflate their levels of high frequency HRV. In addition 
to this, body mass index, long-term smoking behaviors, and moderate and long-term 
alcohol consumption have also been shown to decrease HRV and decrease 
parasympathetic nervous response as measured by high frequency HRV (Harte & 
Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen, & Kupari, 1994; Molifino et 
al., 2009). Individuals with alcohol dependence (based on DSM-5 criteria) will not be 
eligible for the study as this can cause long-term vagal neuropathy (Malpas, Whiteside, & 
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Maling, 1991). Older age is also associated with a global reduction in HRV and research 
has indicated that gender may impact HRV as well (Fagard, 2001; Stein, Kleiger, & 
Rottman 1997; Umetani, Singer, & McCraty, 1998). Interestingly, the level of decreased 
HRV as a result of aging appears to be more pronounced in males in comparison to 
females (Acharya, et al., 2006; Stein, Kleiger, & Rottman 1997; Umetani, Singer, & 
McCraty, 1998). As a result of this, AD participants in the current study will be matched 
with a healthy control based on age and gender.  
The influence of medication should also be considered when interpreting HRV as 
certain classes of medications can cause changes HRV. For example, beta-blockers that 
are used to reduce hypertension and high blood pressure have been shown to improve 
PNS activity and decrease SNS activity (Acharya, et al., 2006). Other medications such 
as selective serotonin reuptake inhibitors (SSRI’s) and benzodiazepines can cause 
adverse changes in blood pressure resulting in orthostatic hypotension (Tinetti & Kumar, 
2010). These medications may interfere with HRV accuracy due to the resultant changes 
in blood pressure. Therefore, medications will be controlled for in the analysis. Lastly, 
acute caffeine ingestion has been shown to cause increased blood pressure, increased 
SNS activity, and decreased HRV (Sondermeijer, Van Marle, Kamen, & Krum, 2002). 
Therefore, participants will be required to refrain from caffeine ingestion 12 hours prior 
to completing the ECG as this may interfere with the HRV reading.  
Alzheimer’s Disease and Heart Rate Variability 
To date, there are no studies exploring changes in autonomic function among 
those diagnosed with AD who are taking Donepezil compared to an age and gender 
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matched healthy control group over a period of six months using supine and standing 
positions. This study will obtain time and frequency-domain HRV data using both supine 
and standing positions at three separate time frames (session 1 [baseline]; session 2 [3 
months]; and session 3 [6 months]). Special attention will be paid to the low and high 
frequency indices as well as the LF/HF modulation ratio and the square root of the mean 
successive differences between adjacent R-R intervals (RMSSD). Data pertaining to the 
covariates described in the HRV confounds section will be obtained each session and 
controlled for in the analyses.  
The results of the few studies examining cardiac autonomic function in AD are 
conflicting, which is likely due to the use of varying methods of measuring heart rate 
variability (e.g., standing vs. supine vs. tilting positions vs. 24-hour). Limitations in the 
methodology of previous studies include the lack of a healthy control group, the use of a 
single time frame (cross sectional design) for data collection, the short period of time in 
which participants were taking Donepezil, the absence of controlling for multiple 
covariates, the failure to report HRV data in normalized (standardized) units (n.u.), the 
absence of a respiration count and a respiratory sinus arrhythmia (RSA) measure, the use 
of animal subjects, and the use of a single position to capture HRV (Allan et al., 2005; Da 
Costa Dias Dias, et al., 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; 
McLaren, et al., 2003; Siepmann, et al., 2006; Umegaki & Khookhor, 2013; Zullii et al., 
2005). Despite the methodological issues with these studies, the majority of the 
researchers have indicated the presence of parasympathetic depression and sympathetic 
exacerbation in persons with AD.  
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In summary, HRV measures can be used to assess cardiac autonomic function, 
and in some studies, ChEls have been shown to improve cardiac autonomic function in 
persons with AD and animal subjects (Da Costa et al., 2013; Giubilei et al., 1998; 
Nordstrom et al., 2013; Umegaki & Khookhor, 2013). The present study will address 
some of the methodological limitations present in previous research. Firstly, participants 
taking the medication Donepezil will be matched with a healthy control of the same age 
(± 3 years) and gender, as both age and gender have been shown to influence HRV 
(Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998). Secondly, the 
participants in the current study will be taking Donepezil for six months and data will be 
obtained at three different time points (baseline, three months, and six months). Few 
studies (including Giubilei et al., 1998; Masuda & Kawamura, 2003; McLaren, et al., 
2003; Siepmann et al., 2006; Umegaki & Khookhor, 2013) have examined the 
cardiovascular benefits of the medication after six weeks. Thirdly, the present study will 
control for the following confounds as previous research has indicated that these factors 
can interfere with HRV measures: age, gender, body mass index (BMI), blood pressure 
(hypertension), medications (blood pressure, allergy, anxiolytic or antidepressant), length 
of time on Donepezil, alcohol use, caffeine use, and physical activity (Harte & Meston, 
2013; Hayano et al., 1990; Koskinen, Virolainen, & Kupari, 1994; Molifino et al., 2009; 
Sandercock, Bromley, & Brodie, 2005; Sondermeijer, Van Marle, Kamen, & Krum, 
2002; Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998). Participants 
will not be eligible for the study if they are taking certain medications that may interfere 
with HRV measures (e.g., anti-depressants), have a recent history of a cardiovascular 
event (e.g., stroke), a recent history of a severe medical condition (e.g., cancer), or suffer 
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from a severe psychological disorder (e.g., bi-polar disorder or schizophrenia). Fourthly, 
the results will be reported in normalized units (n.u.) to emphasize the controlled and 
balanced behavior of the sympathetic and parasympathetic nervous system (Task Force 
on Heart Rate Variability, 1996). The normalization process will also provide more 
meaningful quantities by using percentage values (0%-100%).   
 Fifthly, respiration count will be obtained as heart rate has been shown to 
synchronize with respiratory rhythm. Capturing respiration and adding this to the HRV 
algorithm will also serve to improve the accuracy of parasympathetic data via a measure 
of respiratory sinus arrhythmia (Grossman & Taylor, 2006). This is an important indices 
because heart rate increases during inhalation and decreases during exhalation. 
Respiratory linked variations in heart rate also usually occur in the high frequency (HF) 
range (Lehrer, Vaschillo, and Vaschillo, 2000). Finally, the present study will obtain 
HRV measures in both supine and standing positions as previous studies (Da Costa et al., 
2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo & 
Junqueira, 2008) have demonstrated differences in HRV as a result of varying methods of 
measuring heart rate (e.g., supine vs. standing. vs. tilting vs. 24-hour). Overall, the 
current study will provide additional and more robust evidence into the effects of 
Donepezil on cardiac autonomic function in persons with AD. 
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CHAPTER III 
METHODS AND PROCEDURE  
Participants  
 Recruitment for the present study was completed in February, 2015. There were 
two groups in which individuals were recruited; an Alzheimer’s Disease (AD) group and 
a healthy control group. The AD group is comprised of individuals who were newly 
diagnosed with probable AD of mild to moderate severity as reflected by Mini Mental 
State Examination (MMSE) scores between 16 and 28. The AD group consists of 
individuals taking Donepezil. AD participants were not taking Donepezil for longer than 
3 months at Session 1.  Doses of Donepezil were flexible and typically ranged from 5mg 
to 10mg (after titration). The therapeutic dose may differ for each individual as dose is 
based on the physician’s discretion. If participants discontinued Donepezil at any point 
during the study, they were no longer eligible to participate. The healthy control group 
consists of individuals who were not diagnosed with AD or any other type of cognitive 
disorder, and who were not taking Donepezil. The Healthy Control group self-reported to 
be free from cognitive impairment and obtained MMSE scores within the normal range 
(27-30; Crum, Anthony, Bassett, & Folstein, 1993). Both groups were matched for 
gender as well as age (± 3 years). This matching process is similar to that used by Stein et 
al (1997) who successfully matched male and female older adult participants (± 3 years) 
to study the differing effects of age on HRV between men and women. AD participants 
were matched with a healthy control on an ongoing basis.  
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All participants recruited for the study had at least a 6th grade education level, 
which was ascertained during the phone screen. Probable AD was diagnosed according to 
the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). All 
participants were free from the following conditions: severe and chronic diseases 
affecting general health (e.g., treatment for cancer [within the past year], diagnosed 
cardiovascular disease, chronic kidney or liver disease (end stage renal disease requiring 
dialysis), stroke or cerebrovascular events or disease, or brain tumors. Participants were 
all fluent in English, and did not have any current substance dependence (based on DSM-
5 criteria). Participants were not taking other cholinesterase inhibitors, N-Methyl-D-
aspartate (NMDA) receptor antagonists (e.g., Namenda), anti-psychotics, anticonvulsants 
or tricyclic antidepressants as these medications could interfere with the measures used in 
this study. Participants were not diagnosed with severe psychiatric disorders such as 
psychotic disorders, schizophrenia, or bipolar disorder. Lastly, participants did not have a 
history of multiple head injuries, traumatic brain injury or multiple losses of 
consciousness. 
For sessions 1 and 2, the AD group (n= 12) and the healthy control group (n= 12) 
were larger than the AD group (n= 8) and the healthy control group (n= 8) in session 3. 
This was largely due to attrition rates and user error/unrecoverable data among the AD 
group. More specifically, one AD participant (n= 1) withdrew from the study due to the 
worsening of AD symptoms (cognitive decline) and a second AD participant (n= 1) 
withdrew from the study due to adverse medication reactions which resulted in the 
discontinuation of Donepezil (Aricept®). HRV data from two AD participants (n= 2) 
were lost due to technological difficulties with the receiver (transferring the data to a PC 
48 
  
failed) as well as user error (failure to capture the correct HRV time-interval data).  
Therefore, two separate series of group analyses were conducted. In the first group of 
HRV analyses, the AD group (n= 12) were compared to the healthy control group (n= 
12) over a period of three months (session 1 and session 2; N= 24). In the second set of 
HRV analyses, the AD group (n= 8) were compared to the healthy control group (n= 8) 
over six months (session 1, session 2, and session 3; N= 16).  
In the first set of HRV analyses (N= 24), the AD group consisted of seven males 
(Mean age = 75.71, SD= 6.99) and five females (Mean age = 73.80, SD= 6.14) who were 
matched with the healthy control group based on age and gender. Therefore, the healthy 
control group also consisted of seven males (Mean age = 75.14, SD= 7.43) and five 
females (Mean age = 73.00, SD= 5.70) of similar respective age. In the second set of 
HRV analyses (N= 16), the AD group consisted of five males (Mean age = 77.20, SD= 
6.26) and three females (Mean age = 70.33, SD= 5.51) who were again matched with the 
healthy control group based on age and gender. Therefore, the healthy control group also 
consisted of five males (Mean age = 77.40, SD= 4.92) and three females (Mean age = 
70.33, SD= 6.11) of similar respective age. The total number of participants recruited for 
the present study for sessions 1, 2, and 3 (N= 16) exceeded the total sample size 
generated by the power analysis for the supine position. The total number of participants 
recruited for the present study for sessions 1, 2, and 3 (N= 16) were equal to the total 
sample size generated by the power analysis for the standing position (please refer to the 
Power Analysis Section in Appendix G).       
Recruitment. Participants diagnosed with probable AD were recruited from the 
Glennan Center at Eastern Virginia Medical School (EVMS). The physicians were 
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provided the eligibility criteria for the present study. If a patient met eligibility criteria for 
the AD study, he/she was informed about the study and provided a verbal consent as to 
whether or not they wanted to be contacted by a research team member. No study data 
was obtained from the referring physicians. Flyers advertising for AD participants were 
placed in the Glennan Center, offices of Internal Medicine, the Neuropsychology Center, 
and public bulletin boards (PrimePlus senior center and the YMCA). All methods of 
advertising received Internal Review Board (IRB) approval.  
The age-matched healthy control group were recruited by local advertisement as 
well as referrals from EVMS clinicians. Flyers advertising the need for volunteers were 
placed in the offices of the Glennan Center, Internal Medicine, the Neuropsychology 
Center, and public bulletin boards. Caregivers and local physicians were advised to give 
the flyers to healthy individuals and/or individuals with recently diagnosed Alzheimer’s 
disease that might be interested in participating in the study.  
Once a potential participant provided a verbal consent to be contacted by a 
member of the research team, a research assistant contacted the potential participant via 
telephone and conducted a brief eligibility screen (see Appendix A). This included 
questions surrounding Donepezil (Aricept®) use, the presence or history of 
cardiovascular disease(s) or incidents (e.g., stroke), pertinent psychiatric history (e.g., a 
history of schizophrenia or bipolar disorder), and medication use such as tricyclic anti-
depressants. If the participant was eligible for the study, he/she was invited to attend three 
sessions at Eastern Virginia Medical School (EVMS), Department of Psychiatry and 
Behavioral Sciences, located in Andrews Hall, Suite 244, Norfolk, Virginia. If an AD 
participant was not able to attend the sessions at EVMS due to transportation issues (a 
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common barrier for older adults with AD), the sessions were conducted in the 
participant’s home. In-home sessions only took place if the participant lived within the 
Hampton Roads area. All equipment was easily portable making this a very viable option. 
All three sessions were completed in the same location to reduce the likelihood of the 
environment impacting HRV recordings across sessions. Therefore, AD participants 
either completed all three sessions in the home or at Eastern Virginia Medical School 
(EVMS). A total of four AD participants completed all three HRV sessions in the home 
environment. Participants in the healthy control group completed all sessions at EVMS.  
Proposed Research Design and Methods 
 The present study has three specific hypotheses: 1) participants that are diagnosed 
with mild to moderate AD and who are taking a stable dose of Donepezil (Aricept®) will 
show increased parasympathetic nervous activity over a period of six months. This will 
be indicated by decreases in LF Power (n.u.) and LF/HF Ratio in the standing position at 
session 3 (six months) compared to session 1 (baseline). Thus, there will be a decrease in 
LF Power (n.u.) and LF/HF Ratio from session 1 (baseline) to session 3 (six months) 
when engaging in the orthostatic challenge (supine to standing). In contrast, HF Power 
(n.u.) and RMSSD will increase in the standing position at session 3 (six months) 
compared to session 1 (baseline). Therefore, there will be an increase in HF Power (n.u.) 
and RMSSD from session 1 (baseline) to session 3 (six months) when engaging in the 
orthostatic challenge (supine to standing);  2) Healthy controls will show significant 
increases in HF Power (n.u.) from a supine to standing position at all three sessions. The 
AD group will demonstrate minimal change in HF Power (n.u.) from a supine to a 
standing position at the baseline session, but will show increased HF Power (n.u.) from 
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supine to stand at sessions 2 and 3. Changes in HF Power (n.u.) from a supine to a 
standing position at session 3 will be similar among both AD participants and healthy 
controls; and 3) Donepezil (Aricept®) will improve parasympathetic nervous activity 
through increased acetylcholine transmission, thus supporting the medications use as a 
potential protective agent against cardiac autonomic dysfunction. This study will assess 
heart rate variability (HRV) at baseline (initial session), three months after the first 
session (session 2), and six months after first session (session 3). Each session will last 
approximately 90 minutes in duration. Basic information such as height, weight, blood 
pressure, body mass index (BMI), and heart rate variability measurements will be 
obtained at each session. Again, the primary goal of the present research is to develop an 
understanding of the relationship between cardiac autonomic function and AD while 
identifying the cardiovascular effects of Donepezil on participants with AD.  
Study Protocol 
The present study obtained short-term time-domain (six minutes) and frequency-
domain HRV data over the course of six months. HRV was obtained using a noninvasive 
and reliable method that is widely used to measure cardiac autonomic function. More 
specifically, Polar Performance Technology was utilized to evaluate overall cardiac 
autonomic modulation including sympathetic and parasympathetic nervous system 
function. HRV data were captured at baseline, three month, and six month intervals from 
both AD and healthy control participants in both supine and standing positions as 
recommended by the Task Force on Heart Rate Variability (1996). In order to obtain 
HRV in a standing position, it was recommended that the participant sit in a resting 
position prior to commencing the standing measurement (Risk, Broadbridge, & Cohen, 
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2001). Obtaining HRV readings from a still resting position (supine) to a standing 
position (orthostatic challenge) helped identify any significant changes in SNS and PNS 
activity (Aysin & Aysin, 2007). In the present study, participants were seated in the 
supine position for six minutes while an ECG was administered and HRV was obtained. 
The participants then stood for six minutes and the ECG was re-administered for a second 
time. Research suggests that the heart rate response to standing evaluates the 
cardiovascular response initiated by a change from horizontal to a vertical position (Risk, 
Broadbridge, & Cohen, 2001). The typical heart rate response to standing (increased 
sympathetic activity) is largely mitigated by parasympathetic activity (Risk, Broadbridge, 
& Cohen, 2001).  
The potential impact of hypertension, obesity (BMI), exercise, caffeine use, 
alcohol use, Aricept® dose, and related medications were tracked and evaluated in 
tandem with the effects of Donepezil in the AD participants. This medical and lifestyle-
behavior information was collected for each participant at every session over the six 
month period. All tests used in this protocol had been widely and safely used with diverse 
populations (Allan et al., 2006; Da Costa Dias Dias, et al., 2013; Task Force on Heart 
Rate Variability, 1996; Toledo & Junqueira, 2008). All necessary precautions were taken 
during the course of participation to ensure the safety and wellbeing of the participant. 
The protocol was carried out under the supervision of the principal investigator, Serina 
Neumann, Ph.D. Although the risks associated with participation were minimal, adverse 
events were reported in compliance with EVMS’s Internal Review Board (IRB) policies. 
When a clinically significant physical or psychiatric disorder was identified during the 
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course of participation, an appropriate referral to a medical or psychological treatment 
facility was offered. 
It is important to mention that the current study is part of a larger study exploring 
the effects of Donepezil (Aricept®) on cardiac autonomic function and neuro-cholinergic 
function among patients diagnosed with probable AD. In addition to the time- and 
frequency-domain HRV measures discussed in the present study, neuropsychological 
testing was also completed at the three month intervals. More specifically, 
neuropsychological measures were obtained at baseline, three months and six months in 
tandem with the respective HRV measures. Specific neuropsychological test measures at 
these intervals included the Symbol Digit Modalities Test, Trails Making Tests A and B, 
Controlled Oral Word Association Test, the Test of Premorbid Functioning (TOPF), and 
Hopkins Verbal Learning Test. The same battery of testing was administered during all 
sessions. However, for the purposes of this dissertation, the present study will primarily 
explore Donepezil’s effect on cardiac function in patients with AD through an in vivo, 
non-invasive measure of cardiac autonomic function.   
Measures 
Demographics/Socioeconomic Status (SES) form. This form was used to collect 
demographic information such as age, gender, ethnicity, educational attainment, and job 
and work history (see Appendix B). Age, gender, and ethnicity have been shown to 
influence HRV (Stein, Kleiger, & Rottman 1997; Umetani, Singer, & McCraty, 1998) 
and the Demographics/Socioeconomic Status (SES) form was used to capture this 
information. These variables were then controlled for in the analyses.   
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 Lifestyle Behaviors Questionnaire. The lifestyle behaviors questionnaire was 
used to collect information on lifestyle choices such as tobacco and alcohol use, daily 
caffeine consumption, and hours of physical activity. The questions on this form were 
compiled using selected questions from the following: SCID-NP (Structured Clinical 
Interview for DSM-IV: Non-patient edition), Paffenbarger Physical Activity 
Questionnaire, and Tobacco use interview (see Appendix C). Alcohol use, tobacco use, 
caffeine use, and physical activity can also interfere with HRV measures, and this 
information was captured using the lifestyle behaviors questionnaire and controlled for in 
the analyses (Harte & Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen, & 
Kupari, 1994; Molifino et al., 2009; Sandercock, Bromley, & Brodie, 2005; 
Sondermeijer, Van Marle, Kamen, & Krum, 2002).  
 Medical History Checklist form. The medical history form was used to obtain 
detailed information concerning the participant’s medical history. This included any 
medical conditions surrounding the heart or blood vessels, the brain including 
neurological conditions, and other diseases (see Appendix D). Participants were screened 
for severe medical conditions prior to enrolling in the study and those with severe 
medical conditions such as a recent history of stroke or a diagnosis of multiple sclerosis 
were not be eligible to participate.   
 Medication Update Form. The medication update form was used to record and 
follow changes in medication use and adherence to medical instructions during both 
sessions. This included a list of all medications prescribed to participants, the prescribed 
purpose, as well as the dosage and frequency. Information specific to the administration 
of Donepezil was also gathered (see Appendix E). Certain medications such as beta-
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blockers and antihistamines can also effect blood pressure and HRV (Acharya et al., 
2006; Tinetti & Kumar, 2010). Therefore, these medication types and their prescribed 
doses were controlled for in the analysis. If participants indicated that they had 
discontinued Donepezil, they were no longer eligible to participate in the study. 
Participants who reported adverse side-effects from their medications were referred to 
their physician immediately. These adverse events were then reported in compliance with 
EVMS’s Internal Review Board (IRB) policies.    
Physical and Biological Assessments. The physical and biological assessments 
were used to obtain the following: body mass index (BMI), blood pressure, and heart rate 
variability. These data points were collected at all three sessions. Blood pressure was 
obtained after the participant had been seated for five minutes (See appendix F). High 
body mass index and high blood pressure have been shown to interfere with HRV 
measures, and these were be captured by the physical and biological assessment and 
subsequently controlled for in the analyses (Kleiger, Miller, Bigger, & Moss, 1986; 
Kwon et al., 2008; Naver, Bloomstrand, & Wallin, 1996).  
Measurement of HRV. HRV was measured from a continuous time series of 
beat-to-beat intervals with Polar Performance Technology. Participants were required to 
attach the Polar Performance sensor strap around their chest with the aid of a research 
assistant to ensure the sensor was correctly placed. Participants were also required to 
wear the Polar Performance receiver on their wrist. To estimate vagal activity precisely, 
respiratory rate was assessed for one minute intervals at minute one and minute three of 
the HRV recording. Respiration rate was captured by visual observation (rise and fall of 
chest). Time and frequency-domain measures of HRV were recorded by the Polar 
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Performance Technology. Time domain analyses provided the root mean of successive 
differences in R-R intervals (RMSSD) and heart rate. Based on the Task Force on Heart 
Rate Variability (1996), spectral analyses was performed on the beat-to-beat intervals 
derived from the electrocardiogram (ECG) data collection to obtain both low frequency 
(LF: 0.04-0.15 Hz) and high frequency (HF: 0.15-0.40 Hz) indices. As discussed in the 
previous chapter, LF and HF Power bands measure differential autonomic nervous 
system influences. HF Power primarily reflects respiratory-modulated parasympathetic 
outflow, whereas LF frequency reflects sympathetic control and varying amounts of 
parasympathetic influences (Toledo & Junqueira, 2008; Task Force on Heart Rate 
Variability, 1996). LF Power is also thought to reflect baroreceptor-mediated regulation 
of blood pressure (Bernston, et al., 1997; Friedman & Thayer, 1998). To interpret 
sympathetic influences on the heart, an LF/HF ratio was computed to measure of 
sympathovagal balance (Malliani, Lombard, Pagani, & Cerutii, 1990). This process was 
completed for both supine and standing positions as LF Power in particular shows 
significant changes when positioning is altered from a supine to a standing posture 
(Acharya, et al., 2006; American Heart Association, 1996). Additionally, HRV has been 
shown to vary as a function of gender, age, body mass index, high blood pressure, 
caffeine use, heavy alcohol consumption, tobacco use, and physical activity, and these 
factors were controlled for in the analyses if they correlated with HRV indices. More 
information regarding the use of the HRV data can be found in the HRV data reduction 
section below. 
Data storage. All data were disassociated from participant’s names and other 
identifying information by randomly assigning a four digit ID number. The connection 
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relating the participant name with their ID number was held by the principal investigator 
under lock and key and was destroyed after participant recruitment and data collection 
was completed. Research staff training procedures also incorporated explicit instruction 
regarding procedures for protecting participant confidentiality. 
HRV Data Reduction 
HRV data obtained from the Polar Performance Technology equipment during the 
three sessions were screened for outliers and technological errors and these were 
modified as needed. Once the data were checked for errors, average respiration rate 
adjustments were made to the HF Power bands. The average number of respirations from 
minute one and minute three were then divided by 60, and parameters were created by 
adding and subtracting .03 (Berntson, et al., 1997). The HF Power band represented 
Respiratory Sinus Arrhythmia (RSA). This data was then analyzed using the Kubios 
HRV Analysis Software – Version 2.0 (Biosignal Analysis and Medical Imaging Group, 
2008) which provided reports of HRV frequency-domains. Once these reports were 
generated, data from the Autoregressive approach (AR) were used over the fast Fourier 
transformation (FFT), as the AR method provides better frequency resolution than the 
fast Fourier transformation (Malliani, Pagani, & Lombardi, 1994). The AR technique 
concentrates on the more significant heart rate peaks which ultimately excludes 
additional noise or interference (Berntson et al., 1997).  
As recommended by the Task Force on Heart Rate Variability (1996), both LF 
and HF Power bands were represented in normalized units (n.u.) which emphasizes the 
controlled and balanced behavior of the sympathetic and parasympathetic nervous 
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system. Normalized units are also advantageous as they minimize the effect of the change 
in total power on the values of the LF and HF indices (Task Force on Heart Rate 
Variability, 1996). The two normalized HRV power bands (LF Power n.u.) and (HF 
Power n.u.) were then used to calculate the LF/HF ratio. The LF/HF ratio is a widely 
used HRV index of sympathovagal balance between the two branches of the autonomic 
nervous system (Burr, 2007). The LF/HF ratio is calculated by dividing the LF Power by 
the LF plus the HF Power (Burr, 2007). Additionally, the square root of the mean of the 
squared successive differences between adjacent R-R intervals (RMSSD) was analyzed, 
which reflects the rapid beat-to-beat changes in intervals that are dependent on the 
parasympathetic modulation associated with the respiratory sinus arrhythmia (RSA). For 
each session (session 1 [baseline], session 2 [3 months], and session 3 [6 months]) 
averages from the HF Power n.u., LF Power n.u., RMSSD, and the LF/HF ratio were 
computed for both the Alzheimer’s group and the healthy control group while in the 
supine position and while standing (Toledo & Junqueira, 2008). These four HRV indices 
in both standing and supine positions were compared across three different time frames in 
separate analyses for both groups (between and within). Therefore, there were eight 
different HRV dependent measures for each time point.   
Statistical Analyses 
Power analysis. A priori power analyses were conducted for both supine and 
standing positions over three different time points. The power analysis was used to 
determine an appropriate sample size to achieve adequate power to conduct the ANOVA 
for the three hypotheses. Cohen’s d effect sizes were estimated for both supine and 
standing positions from the Toledo & Junqueira (2008) cross sectional study evaluating 
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HRV in AD patients. The Cohen’s d‘s were considered medium (d’s= .65) for the supine 
AD high frequency power (n.u.) group mean (M= 0.28; SD= 0.03) and the control group 
mean (M= 0.38; SD= 0.04; Cohen, 1988). The Cohen’s d’s were considered large (d’s = 
.82) for the standing AD high frequency power (n.u.) group mean (M= 0.28 n.u.; SD= 
0.03) and the control group mean (M= 0.34; SD= 0.04; Cohen, 1988). Given these effect 
sizes and using a two-tailed alpha of .05, a power analysis was conducted with g*power 
software (version 3.1.7). The results from the power analysis indicated that the total 
number of participants required to obtain a similar effect size in the supine position for a 
repeated measures, between-subjects, ANOVA would be 12. The total number of 
participants required to obtain a similar effect size in the standing position for a repeated 
measures, between-subjects, ANOVA would be 16 (see Appendix G).   
Preliminary analyses. Preliminary analyses were conducted for two separate 
samples. The first sample included participants from session 1 (baseline) and session 2 (3 
months; N= 24) while the second analyses included participants from session 1 
(baseline), session 2 (3 months) and session 3 (6 months; N= 16). Using SPSS software, 
the preliminary analyses examined potential differences between the Alzheimer’s Disease 
(AD) group and healthy controls on sample characteristics at session 1 (baseline), session 
2 (3 months) and session 3 (6 months). This included age, gender, ethnicity, blood 
pressure, body mass index, average hours of weekly exercise, medications (blood 
pressure, allergy, anxiolytic or antidepressant), dose of Donepezil (Aricept®), average 
weekly alcohol use, caffeine use (12 hours prior to HRV recording), exercise (12 hours 
prior to HRV recording), and allergy medication (12 hours prior to HRV recording). 
Though it was initially proposed that tobacco use would be examined, there were no 
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current smokers in any group, and all previous smokers had been tobacco free for more 
than 25 years. Therefore, this variable was removed from the analyses. Data were 
checked for outliers, missing data points, skewness, and kurtosis. Normal distribution 
was determined by calculating z-scores and dividing the skewness values by their 
respective standard errors. If the absolute z-scores for skewness or kurtosis were larger 
than 1.96 corresponding with a significant alpha level of < 0.05, these were considered 
not-normal and subsequently transformed (Field, 2009). Both RMSSD and LF/HF Ratio 
demonstrated numerous indices that were not normally distributed (i.e. skewed). As such, 
all indices of RMSSD and LF/HF Ratio (supine and standing, sessions 1, 2, and 3) were 
uniformly normalized by base 10 logarithm. Following these transformations, RMSSD 
(log10) and LF/HF Ratio (log10) were re-checked for skewness and kurtosis and all were 
considered to be normally distributed (skewness and kurtosis ratio = < 1.96; Field, 2009).  
Once normal distribution among HRV indices was established, the HRV indices 
were correlated with the following sample characteristics: age, gender, ethnicity, blood 
pressure (systolic and diastolic), body mass index, average hours of weekly exercise, 
medications (blood pressure, allergy, anxiolytic or antidepressant), dose of Donepezil, 
average weekly alcohol use, caffeine use (12 hours prior to HRV recording), exercise (12 
hours prior to HRV recording), and allergy medication (12 hours prior to HRV 
recording). Pearson correlation coefficient non-parametric statistics were used for these 
continuous/interval sample characteristics (e.g., HF Power and age). The sample 
characteristics which were significantly correlated (p <.05) to any of the HRV indices 
were controlled for in the ANCOVA analyses. To determine whether or not the 
categorical (binomial) sample characteristics (gender, ethnicity, medication type [blood 
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pressure, allergy, anxiolytic or antidepressant], physical activity 12 hours before HRV 
session, alcohol or caffeine use 12 hours before HRV session, and cold and allergy 
medication 12 hours before HRV session) were correlated with the HRV indices, a 
Kendell’s tau-b statistic was used. This was also recommended given the small sample 
size used in this study (Field, 2009). Sample characteristics that were significantly 
correlated with HRV indices (p= <.05) were controlled for in the ANCOVA model.  
In order to identify between and within group differences among demographic 
variables and sample characteristics, continuous variables were added to a repeated 
measures ANOVA to test for independence. Continuous variables (e.g., average weekly 
alcohol use) that showed significant between and within group differences were added to 
the final ANCOVA model as covariates. Group differences among binomial variables 
were identified using a chi-square test of independence. Those variables which were not 
independent were added to the ANCOVA model as covariates. Lastly, using regression 
analyses, the standardized residuals (variance) from the Aricept® dose were saved as 
separate variables. The differences between the groups were considered statistically 
significant when a p-value was equal or less than 5% (p < .05). The standardized 
residuals were then correlated with the HRV indices using a Pearson correlation 
coefficient non-parametric statistic. The standardized residuals from the Aricept® dose 
that were significantly correlated with HRV indices were added to the final ANCOVA 
model as covariates.  
Primary analyses. Firstly, for the three hypothesis, a 2 (group [AD group versus 
healthy controls]) x2 (task [supine to standing]) x2 (time [baseline and 3 month 
intervals]) repeated measures analysis of covariance (ANCOVA) was computed. This 
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analyses (2x2x2) tested the difference between the AD group versus the healthy control 
group on the time- and frequency-domain HRV indices while engaging in the supine and 
standing tasks over the course of three months. Secondly, a 2 (group [AD group versus 
healthy controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month 
intervals]) repeated measures ANCOVA was computed. This analyses (2x2x3) tested the 
difference between the AD group versus the healthy control group on the time- and 
frequency-domain HRV indices while engaging in the supine and standing tasks over the 
course of six months. 
Each AD participant was successfully matched with a healthy control based on 
age (± 3 years) and gender. The ANCOVA was used to control for the existing covariates 
that were identified in the preliminary analysis. The LF Power (n.u.), HF Power (n.u.), 
LF/HF Ratio (log10) and RMSSD (log10) obtained from the Alzheimer’s and healthy 
control groups were compared across two and three different time points in both supine 
and standing positions. Levene’s tests were checked for homogeneity of variance. For 
those indices where the Levene’s tests were significant, the ratio of highest to lowest 
variance was calculated. It is recommended that if the critical values of the variance 
ratios are less than five, then the variance equality is considered acceptable (Field, 2009). 
Variances for each HRV indices were calculated by squaring the standard deviations of 
the HRV values. All HRV indices which showed Levene’s tests violations (p= <.05) 
were considered acceptable based on the variance ratios.   
Secondary analysis. Tukey’s HSD post-hoc tests for pairwise comparisons were 
used to identify between and within group differences in the 2 (group [AD group versus 
healthy controls]) x2 (task [supine to standing]) x2 (time [baseline and 3 month 
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intervals]) repeated measures ANCOVA and the 2 (group [AD group versus healthy 
controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month 
intervals]) repeated measures ANCOVA. Tukey’s HSD post-hoc tests were computed 
using Tukey’s HSD post-hoc statistics software (Hall, 1998). The data from the 
ANCOVA tables generated in SPSS for LF Power (n.u.), HF Power (n.u.), RMSSD 
(log10) and LF/HF Ratio (log10) were transferred to this software. Separate Tukey’s 
HSD post-hoc tests using the same processes were also conducted to identify any 
significant within group differences from supine to standing.  
Expected study findings.  The expected findings of the present study include the 
following: 1) participants that are diagnosed with mild to moderate AD and who are 
taking a stable dose of Donepezil (Aricept®) will show increased parasympathetic 
nervous activity over a period of six months. This will be indicated by decreases in LF 
Power (n.u.) and LF/HF Ratio (log10) in the standing position at session 3 (six months) 
compared to session 1 (baseline). Thus, there will be a decrease in LF Power (n.u.) and 
LF/HF Ratio (log10) from session 1 (baseline) to session 3 (six months) when engaging 
in the orthostatic challenge (supine to standing). In contrast, HF Power (n.u.) and 
RMSSD (log10) will increase in the standing position at session 3 (six months) compared 
to session 1 (baseline). Therefore, there will be an increase in HF Power (n.u.) and 
RMSSD (log10) from session 1 (baseline) to session 3 (six months) when engaging in the 
orthostatic challenge (supine to standing); 2) Healthy controls will show significant 
increases in HF Power (n.u.) from a supine to standing position at all three sessions. The 
AD group will demonstrate minimal change in HF Power (n.u.) from a supine to a 
standing position at the baseline session, but will show increased changes in HF Power 
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(n.u.) from supine to standing at sessions 2 and 3. Changes in HF Power (n.u.) from a 
supine to a standing position at session 3 will be similar among both AD participants and 
healthy controls; and 3) Donepezil (Aricept®) will improve parasympathetic nervous 
activity through increased acetylcholine transmission, thus supporting the medications 
use as a potential protective agent against cardiac autonomic dysfunction. If these 
hypotheses are not met, this suggests that Donepezil may not possess the cardio-
protective qualities that were initially expected, and the medication may not improve 
cholinergic resources to the extent of enhancing cardiac autonomic function. These 
results would be consistent with the results obtained by Masuda & Kawamura (2003), 
McLaren et al (2003), and Siepmann et al (2006) who indicated a decrease in HF Power 
as result of taking the medication Donepezil. Additionally, if there are no changes in HF 
Power (n.u.) from a supine to a standing position at sessions 2 and 3, this will provide 
further evidence that Donepezil does not possess adequate cardio-protective properties. 
Furthermore, increases in LF Power (n.u.) and a higher LF to HF ratio may indicate the 
continued dominance of the sympathetic nervous system and the presence of 
parasympathetic depression despite the use of Donepezil. More specifically, this will 
indicate a decrease in sympathovagal balance to reflect greater sympathetic modulation.  
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CHAPTER IV 
RESULTS  
Table 1 summarizes demographic information for the 2 (group [AD group versus 
healthy control group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month 
intervals]) repeated measures ANCOVA. Demographic variables which were correlated 
with HRV indices are denoted by p–values.   
 
 
Table 1. Descriptive Statistics and HRV Index Correlations of the AD and HC Sample for 
the 2x2x2 ANCOVA (N= 24).                                                               
Demographic AD HC p 
Total Number of Participants n= 12 n= 12  
Gender 
            Male (n) 
            Female (n) 
 
7 
5 
 
7 
5 
* 
 
Age (years) 
           Male       M (SD) 
           Female   M (SD)   
 
75.71 (6.99) 
73.80 (6.14) 
 
75.14 (7.43) 
73.00 (5.70) 
 
 
Ethnic Background 
Caucasian (n) 
            Male (n) 
            Female (n) 
African-American (n) 
            Male (n) 
            Female (n) 
 
8 
6 
2 
4 
1 
3 
 
10 
7 
3 
2 
0 
2 
* 
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Table 1. Continued  
 
p values were derived from the Pearson correlation coefficients and Kendall’s tau-b 
statistic. Demographics with significant p values are correlated with one or more of the 
HRV indices. Note: *p  <.05  
 
 
Tables 2 and 3 display sample characteristics for the 2 (group [AD group versus 
healthy control group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month 
intervals]) analyses. Sample characteristics that were correlated with HRV indices or 
showed significant group differences are denoted by p-values. Results from the Pearson 
correlation coefficient and Kendall’s tau-b statistic indicated that gender and ethnicity 
were correlated with LF Power (n.u.), HF Power (n.u.), and LF/HF Ratio (log10; p= 
<.05). Body mass index was correlated with all four HRV indices (p= <.05) and allergy 
medication was correlated with RMSSD (log10) only (p= <.05). Therefore, these 
variables were included as covariates in the preliminary ANCOVA. Between group 
differences in weekly alcohol consumption were also identified using a repeated 
measures ANOVA F(1,22) = 6.95, p = .015, 95% CI [2.38, 7.31], η2 = .240. This variable 
was also included in the ANCOVA model as a covariate.  
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Table 2. Sample Characteristics and HRV Index Correlations for the AD Group (n= 12). 
Characteristic  Baseline (S1) 3 Months (S2) p 
Body Mass Index (kg) M (SD) 26.60 (5.59) 27.73 (6.46) * 
Blood Pressure Systolic (mmHg) M (SD) 
                        Diastolic (mmHg) M (SD) 
Dose of Aricept (mg/day) 
139.92 (16.72) 
75.92 (6.68) 
5.00 
130.83 (15.68) 
74.00 (8.64)   
10.00 
 
Blood Pressure Medication Taken (n) 9 9  
Allergy Medication Taken (n) 0 2 ** 
Anxiolytic or Antidepressant Taken (n) 4 3  
Number Alcoholic Drinks Per Week (Avg) M 
(SD) 
2.08 (6.01) 1.33 (4.03) ** 
Hours Exercise Per Week (Avg) M (SD)                           3.85 (3.36) 4.54 (4.04)  
Alcohol or Caffeine last 12 hrs (n) 0 3  
Exercise last 12 hrs (n)                                                            0 0  
Allergy Meds last 12 hrs (n) 0 1  
p values were derived from the Pearson correlation coefficients, Kendall’s tau-b correlation coefficients, and Analysis of 
Variance. Sample characteristics with significant p values are correlated with one or more HRV indices. Note: *p <.05 **p 
<.01     
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Table 3. Sample Characteristics and HRV Index Correlations for the HC Group (n= 12).               
Characteristic Baseline (S1) 3 Months (S2) p 
Body Mass Index (kg) M (SD) 26.25 (5.15) 26.49 (5.49) * 
Blood Pressure Systolic (mmHg) M (SD) 
                        Diastolic (mmHg) M (SD)                     
134.75 (22.54) 
76.58 (12.13)                                      
127.75 (16.30) 
75.33 (8.09)
 
Blood Pressure Medication Taken (n) 6 7  
Allergy Medication Taken (n) 1 1 ** 
Anxiolytic or Antidepressant Taken (n) 1 1  
Number Alcoholic Drinks Per Week (Avg) M (SD)               6.92 (5.39) 7.04 (6.00) ** 
Hours Exercise Per Week (Avg) M (SD) 8.58 (5.10) 5.29 (3.58)                                          
Alcohol or Caffeine last 12 hrs (n) 4 1  
Exercise last 12 hrs (n) 1 2  
Allergy Meds last 12 hrs (n) 1 0  
p values were derived from the Pearson correlation coefficients, Kendall’s tau-b correlation coefficients, and Analysis of 
Variance. Sample characteristics with significant p values are correlated with one or more HRV indices. Note: *p  <.05 ** p   
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Table 4.  Mean and Standard Error of Heart Rate Variability Indices in Healthy Control and Alzheimer’s Disease Groups in 
Supine and Standing Positions at Baseline (Session 1) and Three Month (Session 2) Intervals. 
 
 
HRV Measure 
Baseline (S1) 
         AD                           HC 
    M       SE                  M        SE 
                 3 Months (S2) 
         AD                           HC 
      M       SE                 M        SE 
 
 
p 
 
 
η2 
Supine:       
Low Frequency (n.u.) 58.03 ± 6.66               60.16 ± 8.27 65.61 ± 7.36               68.98 ± 5.32                .330 .056 
High Frequency (n.u.)            41.97 ± 6.66               32.91 ± 7.15 34.39 ± 7.36               31.02 ± 5.32 .617 .015 
RMSSD (log 10) 1.73 ± 0.14                 1.43 ± 0.14 1.53 ± 0.19                 1.52 ± 0.12 .864 .002 
LF/HF Ratio (log10) 0.19 ± 0.15                 0.19 ± 0.15 0.45 ± 0.21                 0.43 ± 0.13 .254 .072 
Standing:      
Low Frequency (n.u.) 72.10 ± 6.63               63.19 ± 5.77 72.25 ± 6.55               68.58 ± 6.36 .330 .056 
High Frequency (n.u.)            27.90 ± 6.63               36.81 ± 5.77 27.75 ± 6.55               31.42 ± 6.36 .617 .015 
RMSSD (log 10) 1.46 ± 0.18                 1.54 ± 0.11     1.49 ± 0.23                 1.38 ± 0.11                .864 .002 
LF/HF Ratio (log10) 0.61 ± 0.19                 0.32 ± 0.14                                 0.62 ± 0.20         0.45 ± 0.15 .254 .072 
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The data for the heart rate variability 2 (group [AD group versus healthy control 
group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month intervals]) 
ANCOVA analyses are presented in Table 4. Based on the ANCOVA, no indices showed 
statistically significant between group differences from supine to standing (see Table 4). 
However, the AD group displayed a trend towards relative sympathetic exacerbation 
from supine to standing at both time points. This was indicated by increases in LF Power 
(n.u.) from supine to standing at baseline and three months. The healthy control group 
also demonstrated an increase in LF Power (n.u.) from supine to standing at baseline and 
three months but to a smaller magnitude (see figure 1). The AD group demonstrated 
lower levels of LF Power (n.u.) in the supine position at both time points in comparison 
to the healthy controls. As expected, the sympathetic exacerbation from supine to 
standing among the AD group was accompanied by relative parasympathetic depression 
in comparison to the healthy control group. Among the AD group, this was indicated by 
decreases in HF Power (n.u.) from supine to standing at baseline and supine to standing 
at three months. In comparison, the healthy control group demonstrated parasympathetic 
enhancement as evidenced by increased HF Power (n.u.) from supine to standing at 
baseline and stable HF Power (n.u.) from supine to standing at three months (see figure 
2). Consistent with lower levels of LF Power (n.u.), the AD group demonstrated higher 
levels of HF Power (n.u.) in the supine position in comparison to healthy controls at both 
time points.  
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Figure 1. Supine to standing mean low frequency power (n.u.) for the AD and HC group 
at baseline (S1) and 3 months (S2). 
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Figure 2. Supine to standing mean high frequency power (n.u.) for the AD and HC group 
at baseline (S1) and 3 months (S2). 
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The relative sympathetic dominance in the standing position among the AD group 
was also reflected by larger LF/HF Ratio (log10). More specifically, the degree in which 
the LF/HF Ratio (log10) for the AD group increased from supine to standing at baseline 
and supine to standing at three months was incrementally larger than the healthy control 
group. In comparison, the healthy control group demonstrated increases in sympathetic 
nervous activity from supine to standing at baseline and supine to standing at three 
months, but to a lower magnitude (see figure 3). As expected, the AD group showed 
reductions of a larger magnitude in the mean squared differences of successive R-R 
intervals (RMSSD [log10]) from supine to standing at baseline in comparison to the 
healthy control group who showed an increase in RMSSD (log10) from supine to 
standing. Interestingly, this was not the case at the three month time period. At this time 
interval, the healthy control group demonstrated smaller magnitudes of RMSSD (log10) 
from supine to standing in comparison to the AD group (see figure 4). Larger magnitudes 
of RMSSD (log10) among the AD group in the supine position at sessions 1 and 2 in 
comparison to healthy controls were also reflective of greater HF Power (n.u.) at these 
time points. Consistent with greater HF Power (n.u.) in the supine position, the AD group 
showed a greater magnitude of RMSSD (log10) at both points and a slightly smaller 
magnitude of LF/HF Ratio (log10) at session 2. Secondary analyses using Tukey’s post-
hoc tests did not reveal any significant between or within group differences for the 2 
(group [AD group versus healthy control group]) x2 (task [supine to standing]) x2 (time 
[baseline and 3 month intervals]) ANCOVA’s 
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Figure 3. Supine to standing mean LF/HF Ratio (log10) for the AD and HC group at 
baseline (S1) and 3 months (S2). 
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Figure 4. Supine to standing mean RMSSD (log10) for the AD and HC group at baseline 
(S1) and 3 months (S2). 
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Table 5 summarizes demographic information for the 2 (group [AD group versus 
healthy control group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 
month intervals]) ANCOVA analyses. Demographic variables which were correlated 
with HRV indices are denoted by p–values. 
 
 
 
Table 5. Descriptive Statistics and HRV Index Correlations of the AD and HC Sample for 
the 2x2x3 ANCOVA (N= 16).  
Demographic AD HC p 
Total Number of Participants n= 8 n= 8  
Gender 
            Male (n) 
            Female (n) 
 
5 
3 
 
5 
3 
* 
 
Age (years) 
           Male       M (SD) 
           Female   M (SD)   
 
77.20 (6.26) 
70.33 (5.51) 
 
77.40 (4.93) 
70.33 (6.11) 
** 
 
Ethnic Background 
Caucasian (n) 
            Male (n) 
            Female (n) 
African-American (n) 
            Male (n) 
            Female (n) 
 
6 
5 
1 
2 
0 
2 
 
7 
5 
2 
1 
0 
1 
* 
p values were derived from the Pearson correlation coefficients and Kendall’s tau-b 
statistic. Demographics with significant p values are correlated with one or more of the 
HRV indices. Note: *p <.05 ** p <.01 
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Tables 6 and 7 display sample characteristics for the 2 (group [AD group versus 
healthy control group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 
month intervals]) analyses. Sample characteristics that were correlated with HRV indices 
or showed significant group differences are also denoted by p-values. Results from the 
Pearson correlation coefficient and Kendall’s tau-b statistic indicated that gender was 
correlated with all four HRV indices (p= <.05) while age was correlated with LF Power 
(n.u.), HF Power (n.u.) and LF/HF Ratio (log10; p= <.01). Ethnicity was only correlated 
with LF Power (n.u.) while body mass index was correlated with LF Power and LF/HF 
Ratio (log10; p= <.05). Systolic blood pressure was correlated with RMSSD (log10) 
while Aricept® dose was correlated with RMSSD (log10) and LF/HF Ratio (log10; p= 
<.05). Anxiolytic and antidepressant medications were correlated with HF Power (n.u.), 
LF Power (n.u.) and LF/HF Ratio (log10; p= <.05). Lastly, average number of hours of 
exercise per week was correlated with LF Power (n.u.), HF Power (n.u.), and LF/HF 
Ratio (log10; p= <.05). Therefore, these variables were included as covariates in the 
ANCOVA’s. Between group differences in weekly alcohol consumption were also 
identified using a repeated measures ANOVA F(1,14) = 7.62, p = .015, 95% CI [2.52, 
7.28], η2 = .352. This variable was also included in the ANCOVA model as a covariate.  
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Table 6. Sample Characteristics and HRV Index Correlations for the AD Group (n= 8).       
Characteristic  Baseline (S1) 3 Months (S2) 6 Months (S3) p 
Body Mass Index (kg) M (SD)                          25.86 (5.99) 26.56 (5.58) 25.49 (5.25) * 
Blood Pressure Systolic (mmHg) M (SD) 139.88 (19.50) 132.63 (15.70) 127.38 (17.86) * 
                        Diastolic (mmHg) M (SD) 75.00 (7.46) 75.63 (7.96) 72.00 (8.30)  
Dose of Aricept (mg/day) 5.00 10.00 10.00 * 
Blood Pressure Medication Taken (n) 6 6 5  
Allergy Medication Taken (n) 0 2 2  
Anxiolytic or Antidepressant Taken (n) 2 1 1 * 
Number Alcoholic Drinks Per Week (Avg) M (SD) 3.13 (7.28) 2.00 (4.90)                              0.38 (0.74)                 * 
Hours Exercise Per Week (Avg) M (SD) 4.96 (3.53) 5.81 (4.21) 5.47 (2.63) * 
Alcohol or Caffeine last 12 hrs (n)                              0 3 0  
Exercise last 12 hrs (n)                                                 0 0 0  
Allergy Meds last 12 hrs (n) 0 0 1  
p values were derived from the Pearson correlation coefficients, Kendall’s tau-b statistic, and Analysis of Variance. Sample 
characteristics with significant p values are correlated with one or more of the HRV indices. Note: *p <.05      
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Table 7. Sample Characteristics and HRV Index Correlations for the HC Group (n= 8).            
Characteristic  Baseline (S1) 3 Months (S2) 6 Months (S3) p 
Body Mass Index (kg) M (SD)                          25.03 (5.20) 25.18 (5.50) 24.79 (5.06) * 
Blood Pressure Systolic (mmHg) M (SD) 135.50 (24.58) 126.75 (15.49) 129.13 (16.66) * 
                        Diastolic (mmHg) M (SD) 75.50 (11.61) 74.88 (6.33) 75.50 (8.38)  
Blood Pressure Medication Taken (n) 4 5 3  
Allergy Medication Taken (n) 1 1 0  
Anxiolytic or Antidepressant Taken (n) 1 1 1 * 
Number Alcoholic Drinks Per Week (Avg) M (SD) 8.50 (5.15) 8.00 (4.96) 7.31 (5.38)                                 * 
Hours Exercise Per Week (Avg) M (SD) 9.00 (4.17) 5.81 (4.09) 6.38 (3.29)                 * 
Alcohol or Caffeine last 12 hrs (n)                              3 1 1  
Exercise last 12 hrs (n)                                                 1 1 1  
Allergy Meds last 12 hrs (n) 1 0 0  
p values were derived from the Pearson correlation coefficients, Kendall’s tau-b statistic, and Analysis of Variance. Sample 
characteristics with significant p values are correlated with one or more of the HRV indices. Note: *p  <.05
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Table 8.  Mean and Standard Error of HRV Indices in Healthy Control and Alzheimer’s Disease Groups in Supine and 
Standing Positions at Baseline, Three Month, and Six Month Intervals.  
 
 
HRV Measure 
Baseline (S1) 
      AD                       HC 
 M        SE         M          SE 
  3 Months (S2) 
       AD                     HC 
  M           SE       M         SE 
6 Months (S3) 
       AD                      HC 
  M          SE          M       SE 
 
 
p 
 
 
η2 
Supine:        
Low Frequency 
(n.u.) 
52.43 ± 8.26   69.04 ± 6.07     63.49 ± 10.15   60.35 ± 5.59 60.76 ± 7.76      61.08 ± 5.79 .415 .097 
High Frequency 
(n.u.)            
47.58 ± 8.27   30.96 ± 6.07          36.51 ± 10.15   39.65 ± 5.59 39.24 ± 7.76      38.91 ± 5.78 .339 .102 
RMSSD (log 10) 1.82 ± 0.19      1.29 ± 0.16             1.59 ± 0.23         1.66 ± 0.12 1.83 ± 0.19          1.53 ± 0.12 .442 .060 
LF/HF Ratio (log10) 0.43 ± 0.19       0.19 ± 0.14 0.37 ± 0.25         0.23 ± 0.14 0.23 ± 0.17          0.22 ± 0.12 .051 .440 
Standing:       
Low Frequency 
(n.u.) 
67.90 ± 7.56   58.63 ± 6.27 66.44 ± 8.76     65.70 ± 7.18 74.00 ± 7.41      65.04 ± 7.76 .415 .097 
High Frequency 
(n.u.)            
32.10 ± 7.56   41.38 ± 6.27 33.56 ± 8.76     34.30 ± 7.18 26.00 ± 7.40      34.93 ± 7.66 .339 .102 
RMSSD (log 10) 1.63 ± 0.23       1.54 ± 0.14 1.63 ± 0.26        1.40 ± 0.15 1.59 ± 0.20          1.47 ± 0.17 .442 .060 
LF/HF Ratio (log10) 0.43 ± 0.19       0.19 ± 0.14              0.49 ± 0.26        0.34 ± 0.16 0.64 ± 0.24     0.40 ± 0.21 .051 .440 
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The data for the heart rate variability 2 (group [AD group versus healthy control 
group]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month intervals]) 
analyses are presented in Table 8. Results from the 2 (group [AD group versus healthy 
controls]) x2 (task [supine to standing]) x3 (time [baseline, 3 month and 6 month 
intervals]) ANCOVA’s, did not demonstrate statistically significant between group 
differences from supine to standing. As in the 2 (group [AD group versus healthy control 
group]) x2 (task [supine to standing]) x2 (time [baseline and 3 month intervals]) analyses, 
between group differences among LF Power (n.u.), HF Power (n.u.), LF/HF Ratio 
(log10) and the mean squared differences of successive R-R intervals (RMSSD [log10]) 
were not statistically significant. There were no significant within group differences 
among the HRV indices from supine to standing at the three time points. Despite the lack 
of statistical significance, the AD group demonstrated a trend towards larger increases in 
LF Power (n.u.) from supine to standing in comparison to the healthy control group at all 
three sessions. The healthy control group demonstrated lower levels of sympathetic 
exacerbation from supine to standing at session 1, supine to standing at session 2, and 
supine to standing at session 3 in comparison to the AD group. Additionally, the level of 
LF Power (n.u.)/sympathetic nervous activity exacerbated over time for the AD group in 
comparison to the healthy control group which remained relatively stable. Results from 
the 2 (group [AD group versus healthy control group]) x2 (task [supine to standing]) x3 
(time [baseline, 3 month and 6 month intervals]) ANCOVA also indicated that the 
healthy control group demonstrated higher levels of LF Power (n.u.) and lower levels of 
HF Power (n.u.) in the supine position at sessions 1 and 3 compared to the AD group, but 
once the AD group initiated the standing task, their LF Power (n.u.) exacerbated at a 
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much larger rate than the healthy control group (see figure 5). As expected, the increase 
in LF Power (n.u.) resulted in a decrease in HF Power (n.u.) among both groups with the 
exception of the healthy control group at baseline who demonstrated an increase in HF 
Power (n.u.) from supine to stand. Overall, the AD group demonstrated a higher 
magnitude of parasympathetic depression in comparison to the healthy control group at 
all three time points when engaging in the orthostatic challenge (supine to standing; see 
figure 6).  
 
 
 
 
Figure 5. Supine to standing mean low frequency power (n.u.) for the AD and HC group 
at baseline (S1), 3 months (S2), and 6 months (S3). 
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Figure 6. Supine to standing mean high frequency power (n.u.) for the AD and HC group 
at baseline (S1), 3 months (S2), and 6 months (S3). 
 
 
 
Results from the 2 (group [AD group versus healthy control group]) x2 (task 
[supine to standing]) x3 (time [baseline, 3 month and 6 month intervals]) ANCOVA did 
not indicate significant between group differences for the LF/HF Ratio (log10) but were 
very close F(1, 8) = 5.50, p = .051, 95% CI [0.19, 0.50], η2 = .440. Results from the 
ANCOVA also indicated a medium effect for the LF/HF Ratio (log10) between group 
differences. The mean LF/HF Ratio (log10) reflected greater sympathetic dominance 
(larger LF/HF ratios) in both supine and standing positions at sessions 1, 2 and 3 among 
the AD group in comparison to the healthy control group. When transitioning from 
supine to standing position, the AD group demonstrated larger increases in LF/HF Ratio 
(log10) as well (see figure 7). This is consistent with the relative sympathetic 
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exacerbation and parasympathetic depression demonstrated by the AD group as 
evidenced by increased LF Power (n.u.) from supine to standing and decreased HF Power 
(n.u.) from supine to standing. Lastly, the AD group showed a larger magnitude of mean 
squared differences of successive intervals (RMSSD [log10]) from supine to standing at 
all three time points in comparison to the healthy control group. The greater magnitude of 
RMSSD (log10) among the AD group is reflective of the larger variations in LF Power 
(n.u.) and HF Power (n.u.) from supine to standing (see figure 8). Secondary analyses 
using Tukey’s post-hoc tests revealed significant between group differences at baseline 
for RMSSD (log10) between the AD group (M=1.82, SD= 0.54) and the healthy control 
group (M=1.29, SD= 0.46) while in the supine position (p <.05). 
 
 
 
 
Figure 7. Supine to standing mean LF/ HF Ratio (log10) for the AD and HC group at 
baseline (S1), 3 months (S2), and 6 months (S3). 
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Figure 8. Supine to standing mean RMSSD (log10) for the AD and HC group at baseline 
(S1), 3 months (S2), and 6 months (S3). 
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CHAPTER V 
SUMMARY AND DISCUSSION 
The goal of the present study was to explore the effects of Alzheimer’s disease 
(AD) pathology on cardiac autonomic function for individuals diagnosed with AD and 
taking the medication Donepezil (Aricept®). Previous research and epidemiological data 
using HRV technology have indicated variable disturbances of autonomic function in 
persons with AD (Allan, et al., 2007; Giubilei et al., 1998; Masuda & Kawamura, 2003; 
Siepmann et al., 2006; Toledo & Junqueira, 2008; Zulli et al., 2005). More specifically, 
cardiac autonomic dysfunction is prevalent among individuals with AD as reflected by 
exacerbated sympathetic nervous activity and decreased parasympathetic nervous activity 
(Allan et al., 2007; Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al., 
2006; Toledo & Junqueira, 2008; Zulli et al., 2005). This sympathovagal imbalance 
(sympathetic dominance) is a recognized risk factor for cardiovascular mortality, 
characterized by higher risk of arrhythmias, parasympathetic depression, syncope, and 
sudden death (Allan et al., 2007; Kleiger, Miller, Bigger, & Moss, 1986).  
Prior research has indicated that the enhancement of sympathetic nervous activity 
and parasympathetic depression among persons with AD is even more profound 
following a shift from a supine to a standing position (Toledo & Junqueira, 2008). This 
shift in position (known as the orthostatic challenge), is an excellent way to measure 
cardiac autonomic dysfunction due to the increase in sympathetic nervous activity 
triggered from the supine to standing movement (Aysin & Aysin, 2007).  
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As poor cardiovascular health appears to be a mechanism of AD pathology, 
research looking into the potential cardiovascular benefits of cholinesterase inhibitors 
(ChEls) has gained much interest (Da Costa Dias et al., 2013; Giubilei et al., 1998; 
Masuda & Kawamura, 2003; McLaren et al., 2003; Nordstrom et al., 2013; Siepmann et 
al., 2006; Umegaki & Khookhor, 2013). However, results from studies exploring the 
cardio protective benefits of ChEls have been mixed (Da Costa Dias et al., 2013; Giubilei 
et al., 1998; Masuda & Kawamura, 2003; McLaren et al., 2003; Siepmann et al., 2006; 
Umegaki & Khookhor, 2013). These studies also contain various methodological 
limitations including the use of a now discontinued ChEls (Giubilei et al., 1998), the 
short duration of study (e.g., two weeks; McLaren, et al., 2003; Umegaki & Khookhor, 
2013), measuring changes at a single, variable (± 4.8 weeks) time frame (Da Costa Dias 
Dias et al., 2013), the use of animal subjects as opposed to human subjects (Umegaki & 
Khookhor, 2013), the absence of normalized units when exploring changes in HRV over 
time (Masuda & Kawamura, 2003; Toledo & Junqueira, 2008; Umegaki & Khookhor, 
2013), the lack of a healthy control group comparison (McLaren, et al., 2003), and 
controlling for few factors which have been shown to interfere with HRV measurement 
(Da Costa Dias Dias et al., 2013; Giubilei et al., 1998; Masuda & Kawamura, 2003; 
McLaren, et al., 2003; Siepmann et al., 2006; Umegaki & Khookhor, 2013).       
 In the present study, differences in HRV among individuals with Alzheimer’s 
disease versus healthy controls were studied over a period of six months in both supine 
and standing positions. HRV was obtained through the utilization of non-invasive 
electrocardiogram (ECG) technology using frequency-domain (LF Power, HF Power, 
RMSSD, LF/HF Ratio) and time-domain (six minutes) measures. The results of the 
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current study indicated a trend towards greater reductions in parasympathetic function 
and greater increases in sympathetic function among the AD group in comparison to the 
healthy controls during the orthostatic challenge. This was the case across all three time 
points. More specifically, the AD group showed a lower magnitude of normalized high 
frequency power in comparison to healthy controls (session 1= 9.28% [lower]; session 2= 
3.67% [lower]; session 3= 8.93% [lower]) while in the standing position. This trend was 
accompanied by a greater LF/HF ratio among the AD group (session 1= 0.24% [greater]; 
session 2= 0.15% [greater]; session 3= 0.24% [greater]) reflecting greater sympathovagal 
imbalance. Statistically, this trend towards greater LF/HF Ratio among the AD group 
versus healthy controls at all three sessions also corresponded with a medium effect size 
(95% CI [0.19, 0.50], η2 =.440). Therefore, Cohen’s effect size value suggested a 
moderate level of practical significance, which is reflected by the large trend toward 
sympathetic exacerbation among the AD group when engaging in the orthostatic 
challenge. Despite this trend toward sympathetic exacerbation among the AD group 
while engaging in the orthostatic challenge, it is important to note that the results from 
the ANCOVA’s were not statistically significant. In addition, although there was a 
medium effect size for the LF/HF ratio, it is important to consider the potentially large 
amount of error variance that may be inherent with a small sample. Therefore, these 
results need to be interpreted with caution.   
During the supine task, the AD group showed a larger magnitude of normalized 
high frequency power in comparison to the healthy control group (session 1= 16.62% 
[greater]; session 2= 3.37% [greater]; session 3= 0.33% [greater]). However, this was 
substantially reduced when engaging in the standing task (orthostatic challenge). 
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Therefore, the supine position may mask the presence of cardiac autonomic dysfunction, 
which is then revealed when the individual engages in the orthostatic challenge. While 
engaging in the orthostatic challenge, the healthy control group showed an increase in 
normalized high frequency power from supine to standing at session 1, indicating better 
sympathovagal balance when changing posture. Not surprisingly, the healthy control 
group demonstrated greater high frequency power at session 1 (9.28% [greater]) in 
comparison to the AD group while engaging in the orthostatic challenge. At sessions 2 
and 3, the healthy control group demonstrated a reduction in high frequency power from 
supine to standing. However, the magnitude of the high frequency power generated by 
the healthy control group while in the standing position at sessions 2 (3.67% [greater]) 
and 3 (8.93% [greater]) was still comparatively larger than the AD group. Therefore, the 
healthy control group generated a greater magnitude of high frequency power at all three 
sessions when engaging in the orthostatic challenge.  
Based on a meta-analysis of short-term heart rate variability recordings among 
healthy adults (≥ 18 years; Nunan, Sandercock, & Brodie, 2010), the mean normal values 
of low frequency power (expressed in normalized units) should be approximately 52% 
(SD= 10), while mean normal values of high frequency power (expressed in normalized 
units) should be approximately 40% (SD= 10). While in the supine position, the AD 
group generated more similar magnitudes of low and high frequency power with respect 
to this normative sample. However, while engaging in the orthostatic challenge, the 
healthy control group generated more similar magnitudes of low and high frequency 
power with respect to this normative sample. This may provide further corroborating 
evidence for more healthy cardiac autonomic function among the healthy control group 
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while engaging in the orthostatic challenge. It is important to mention that the Nunan, 
Sandercock, & Brodie (2010) study combined all HRV positions (e.g., supine and 
standing) and did not provide separate mean scores for older adults. Therefore, the 
conclusions that can be drawn between the data obtained in the present study and this 
normative data are limited.    
The results from the current study are similar to that of three previous studies that 
identified a significant reduction in high frequency power among AD participants 
undergoing ChEls treatment (McLaren et al., 2003; Siepmann et al., 2006; Masuda & 
Kawamura, 2003). Additionally, the current study supports general findings from authors 
Toledo & Junqueira (2008) and Zulli et al (2005) who identified relative parasympathetic 
depression and sympathetic exacerbation among individuals with AD versus healthy 
controls. However, AD participants in the Toledo & Junqueira (2008) study were not 
undertaking ChEls treatment and also demonstrated parasympathetic depression and 
sympathetic exacerbation in the supine position. Findings from the current study suggest 
that individuals with AD who were taking the medication Donepezil (Aricept®) showed 
better high frequency power in the supine position at sessions 1, 2 and 3 in comparison to 
healthy controls. These findings may indicate that cardiac autonomic function is 
improved among individuals with AD when in the supine position as a result of the 
cholinesterase inhibitor Donepezil (Aricept®). However, when the AD participants are 
standing, the potential beneficial effects of Aricept® appear to be minimized.  
Previous research has demonstrated that changes in blood pressure, high and low 
frequency band power show significant changes when positioning is altered from a 
supine to a standing posture (Acharya, et al., 2006; American Heart Association, 1996; 
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Aysin & Aysin, 2007). This was particularly evident among the AD group who showed 
exacerbated low frequency power and reduced high frequency power from supine to 
standing positions at all three time points in comparison to healthy controls. This 
decrease in high frequency power among the AD group when engaging in the orthostatic 
challenge may be a more accurate reflection of cardiac autonomic dysfunction given that 
the orthostatic challenge is commonly used to measure ANS function (Aysin & Aysin, 
2007). As there is a strong relation between the autonomic nervous system and blood 
pressure via the baroreceptor reflex (the baroreceptor reflex helps restore blood pressure 
by increasing heart rate), it is possible that the AD group experienced greater oscillations 
in blood pressure (e.g., orthostatic hypotension) while engaging in the orthostatic 
challenge (Berntson, 1997). Previous research has indicated a strong relation between 
high blood pressure and greater low frequency power (sympathetic exacerbation) among 
hypertensive individuals (Piccirillo, Munizzi, Fimognari, & Marigliano., 1996).  
Although findings from the current study are similar to that of previous research 
(Masuda & Kawamura, 2003; McLaren et al., 2003; Siepmann et al., 2006; Toledo & 
Junqueira., 2008; Zulli et al., 2005), it is important to mention that these results also 
contradict previous findings as well (Giubilei, et al., 1998). For example, authors Giubilei 
et al (1998) identified improved cardiac autonomic function among individuals with AD 
who were undertaking ChEl treatment. More specifically, the AD group showed similar 
magnitudes of high frequency power and low frequency power compared to healthy 
controls while in the tilting position following ChEl treatment. However, there were 
various limitations to this study including the short time frame studied (one month) and 
the use of a now discontinued ChEls. Overall, results from the present study extend the 
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majority of the previous findings regarding autonomic dysfunction in persons with 
Alzheimer’s disease and healthy older adults, reinforcing patterns of parasympathetic 
depression and sympathetic exacerbation (Masuda & Kawamura, 2003; McLaren, et al., 
2003; Siepmann et al., 2006; Toledo & Junqueira, 2008, 2009; Zulli et al., 2005).  
With regards to the expected findings outlined previously, the AD group showed 
greater high frequency power at session 1 (16.62% [greater]), and slightly better high 
frequency power at session 2 (3.37%[greater]) and session 3 (0.33% [greater]) in 
comparison to the healthy control group in the supine position. Although the magnitude 
of high frequency power at session 3 had decreased by 8.34% from session 1 for the AD 
group, the magnitude of high frequency power was still larger than that of the healthy 
control group at all three sessions while in the supine position. The larger proportion of 
high frequency power generated by the AD group at baseline may be related to the 
proximity to the first dose of Aricept® and the stabilization (therapeutic dose) of the 
medication at the six month time point. More specifically, two previous studies have 
indicated initial increases in high frequency power after short periods of ingestion of a 
ChEls (two weeks and one month respectively; Giubilei et al., 1998; Umegaki & 
Khookhor, 2013). This may be of particular significance because researchers Rogers et al 
(1998) found that the effects of Donepezil on cognitive functioning were most 
pronounced at the 12 week visit (three months). These neurocholinergic effects also 
persisted with no decrease in magnitude at weeks 18 and 24 (Rogers, 1998). During the 
baseline phase, AD participants were fairly early in their ChEl treatment (less than three 
months) and were exposed to lower doses (5mg) of Aricept®. By session 2 (three 
months) and session 3 (six months), AD participants were taking Aricept® for an 
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extended period of time and were titrated to larger doses (10mg). Therefore, the results 
from the current study may suggest that chronic administration of Aricept® could have 
positive effects of PNS activity at the six month interval in comparison to healthy 
controls through an increase in cholinergic resources. However, the AD group 
demonstrated large reductions in high frequency power from baseline to six months 
particularly in the standing position. Therefore, this suggests that participants diagnosed 
with mild to moderate AD continued to show cardiac autonomic dysfunction over a 
period of six months while taking Donepezil (Aricept®). Given that the orthostatic 
challenge has been widely used as a measure of cardiac autonomic function, the results 
demonstrating decreases in high frequency power among the AD group when in the 
standing position appear to be more compelling.  
Secondly, it was hypothesized that healthy controls would show significant 
increases in high frequency power from a supine to standing position at all three sessions, 
while the AD group would demonstrate minimal change in high frequency power from a 
supine to standing position at the baseline session, but would gradually show increased 
high frequency power from supine to standing at sessions 2 and 3. Results from this study 
indicated that healthy controls demonstrated both increases in high frequency power from 
supine to standing at session 1 (10.42% [increase]) and decreases in high frequency 
power from supine to standing at sessions 2 (5.35% [decrease]) and 3 (3.98% [decrease]). 
In contrast, the AD group showed larger decreases in high frequency power from supine 
to standing at all three sessions (session 1= 15.48% [decrease]; session 2= 6.82% 
[decrease]; session 3= 13.24% [decrease]). However, these results were not statistically 
significant. The current HRV literature also indicates that healthy older adults have the 
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tendency to show reductions in high frequency power from supine to standing positions 
as well (Toledo & Junquiera, 2008). Although it was hypothesized that the healthy 
controls would display increases in high frequency power from supine to standing, the 
trend for reductions in high frequency power from supine to standing among the healthy 
older adults at sessions 2 and 3 found in the present study are consistent with previous 
findings (Giubilei, et al., 1998; Toledo & Junquiera, 2008).  
Thirdly, it was hypothesized that Donepezil (Aricept®) would improve 
parasympathetic nervous activity through increased acetylcholine transmission, thus 
supporting the medications use as a potential protective agent against cardiac autonomic 
dysfunction. Results from this study indicate that high frequency power was greater for 
individuals with AD in comparison to healthy controls at sessions 1, 2 and 3 in the supine 
position only. Therefore, it is possible that Donepezil (Aricept®) may provide cardio-
protective factors which are more evident in the supine position. However, as mentioned 
previously, the potential cardiac benefits of Donepezil (Aricept®) appear to be nullified 
during a standing task. These results are consistent with the results obtained by Masuda 
& Kawamura (2003) and McLaren et al (2003) who indicated a decrease in high 
frequency power as result of taking the medication Donepezil. Increases in low frequency 
power and a larger LF/HF ratio among the AD group also indicated the continued 
dominance of the sympathetic nervous system and the presence of parasympathetic 
depression despite the use of Donepezil. Thus, there is a tendency towards 
sympathovagal imbalance reflecting greater sympathetic modulation during a supine to 
standing task among the AD group.  
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One of the goals of the present study was to address the methodological 
limitations of studies exploring the effects of ChEls on HRV among individuals with AD. 
Firstly, participants taking the medication Donepezil were matched with a healthy control 
of the same age (± 3 years) and gender. The previous studies exploring the effects of 
ChEl treatment on individuals with AD did not match AD participants with healthy 
controls (Da Costa Dias et al., 2013; Masuda & Kawamura, 2003; McLaren, et al., 2003; 
Umegaki & Khookhor, 2013). Secondly, the participants in the current study were taking 
Donepezil for six months and data was obtained at three different time points (session 1 
[baseline], session 2 [three months], and session 3 [six months]). Few studies have 
examined the cardiovascular benefits of the medication after six weeks (Da Costa Dias et 
al., 2013; Masuda & Kawamura, 2003; McLaren, et al., 2003; Siepmann et al., 2006; 
Umegaki & Khookhor, 2013). Thirdly, the present study controlled for the following 
confounds, which are known to influence HRV measures: age, gender, body mass index 
(BMI), blood pressure (systolic and diastolic), medications (blood pressure, allergy, 
anxiolytic or antidepressant), dose on Donepezil (Aricept®), alcohol use, caffeine use, 
and physical activity (Harte & Meston, 2013; Hayano et al., 1990; Koskinen, Virolainen, 
& Kupari, 1994; Molifino et al., 2009; Sandercock, Bromley, & Brodie, 2005; 
Sondermeijer, Van Marle, Kamen, & Krum, 2002; Stein, Kleiger, & Rottman 1997; 
Umetani, Singer, & McCraty, 1998). The results from the Pearson correlation coefficients 
and the Kendall’s tau-b correlation coefficients demonstrated that age, body mass index, 
blood pressure, medications (blood pressure, allergy, anxiolytic or antidepressant), dose 
of Aricept, and physical activity all correlated with one or more of the HRV indices. 
Significant between group differences in alcohol use were also identified from the 
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between subjects ANOVA’s. Thus, it is probable that these factors could influence 
variations in multiple HRV indices.  
With regards to the statistical analyses, although there were fairly clear mean 
differences in HRV indices and a large effect in LF/HF Ratio between the AD group and 
the healthy control group, none of these mean comparisons were statistically significant. 
As HRV is very sensitive to various confounding conditions, it is possible that some of 
the variance in HRV in previous studies can be accounted for by these confounding 
factors. For example, the Toledo & Junquiera (2008) study indicated significant 
differences between individuals with AD and healthy controls from a supine to standing 
position. However, the mean age of the AD group (Mean age= 79.6) was higher than the 
age of the control group (Mean age= 68.6). Therefore, some of this between group 
variance might be explained by age differences between the AD group and the healthy 
control group.   
Fourthly, some of the indices (low frequency power and high frequency power) 
used in this study were reported in normalized units to emphasize the controlled and 
balanced behavior of the sympathetic and parasympathetic nervous system (Task Force 
on Heart Rate Variability, 1996). Normalized units display sympathetic and 
parasympathetic activity as a percentage (0%-100%). This allows the clinician to easily 
ascertain changes in sympathetic versus parasympathetic output over time (e.g., when 
using a repeated measures design) but also provides the opportunity to determine 
sympathetic versus parasympathetic modulation (Task Force on Heart Rate Variability, 
1996). Previous studies have not utilized normalized units to monitor changes in HRV 
among individuals with AD taking the medication Donepezil (Aricept®; Masuda & 
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Kawamura, 2003; McLaren, 2003; Umegaki & Khookhor, 2013). Using normalized units 
also provides the opportunity to compare HRV indices with normative data or previous 
studies that express HRV data in normalized units.  
Fifthly, respiration count was captured and added to the HRV algorithm using the 
Kubios HRV Analysis Software. This was accomplished by observing the frequency of 
breaths (rise and fall of the chest) at two separate one minute intervals (minute one and 
minute three) during the supine and standing position at all three sessions. As discussed 
previously, the adjustment using respiration in a HRV algorithm is known as respiratory 
sinus arrhythmia (RSA). The RSA is generated by integrating changes in heart rate 
during inhalation (heart rate increases) and exhalation (heart rate decreases). Respiratory 
linked variations in heart rate usually occur in the high frequency range (Lehrer, 
Vaschillo, and Vaschillo, 2000) and thus, RSA has been shown to provide a more 
accurate index of cardiac vagal tone and parasympathetic activity (Grossman & Taylor, 
2006). Finally, the present study obtained HRV measures in both supine and standing 
positions as previous studies have demonstrated differences in HRV as a result of varying 
methods of measuring heart rate (e.g., supine vs. standing. vs. tilting vs. 24-hour; 
(Giubilei et al., 1998; Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo & 
Junqueira, 2008; Zulli et al., 2005).  
Clinical Implications for Health Psychology 
Given the strong evidence for cardiac autonomic dysfunction among individuals 
with AD as evidenced in the present study, HRV technology could be utilized to capture 
sympathetic and parasympathetic nervous activity among patients who are at risk for 
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developing AD (e.g., genetically or recently diagnosed with mild cognitive impairment). 
Subsequent changes in HRV (e.g., low frequency dominance) in tandem with decreased 
cognitive status could provide corroborating evidence for reductions in acetylcholine 
production, transmission, and probable dementia. As results from this study demonstrated 
large decreases in high frequency power during the orthostatic challenge among the AD 
group, it is may be beneficial to obtain HRV recordings in two separate positions. More 
specifically, when obtaining HRV data from individuals with suspected AD, HRV 
recordings should be performed in both the supine and standing position as the orthostatic 
challenge revealed greater cardiac autonomic dysfunction among the AD group when 
changing position. If the clinician obtains HRV readings in the supine position only, then 
the presence of cardiac autonomic dysfunction may be missed. Once the clinician obtains 
HRV data, results could be communicated to the patient’s primary care physician and the 
interdisciplinary care team who may use this information to guide treatment 
interventions. For example, if the individual shows impaired cardiac autonomic function 
via sympathetic dominance, referral to a health psychologist for HRV biofeedback, 
relaxation training, or progressive muscle relaxation may reduce the risk for potential 
cardiac events. Both relaxation training and progressive muscle relaxation exercises have 
been successfully implemented with older adults (Hirokawa, 2004; Morone & Greco, 
2007). One particular study significantly reduced hypertension among older adults using 
guided relaxation training (Tang, Harms, Speck, Vezeau, & Jesurum, 2009).  
Another clinical intervention that may reduce the likelihood of future cardiac 
events is slow (diaphragmatic) breathing. Research has indicated that people are capable 
of voluntarily producing substantial increases in respiratory sinus arrhythmia (RSA) or 
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high frequency power using biofeedback techniques (Lehrer, Vaschillo, & Vaschillo, 
2000). It is well established that HRV is systematically influenced by breathing 
frequency, with higher frequency being generated by slower respiration (Lehrer & 
Gevirtz, 2014). As such, when breathing rate is reduced, R–R interval fluctuations and 
spectral power are increased (Eckberg, 2003). The recommended rate of breathing to 
achieve increased R-R fluctuations and higher frequency output is six breaths per minute 
(Lehrer & Gevirtz, 2014). In order to achieve a rate of six breaths per minute, a pacing 
stimulus can be presented on a computer display screen prompting patients when to 
slowly inhale and exhale using their diaphragm (diaphragmatic breathing; Lehrer, 
Vaschillo, and Vaschillo, 2000). The introduction of HRV biofeedback technology then 
teaches the patient to breathe approximately in phase with heart rate changes through a 
different visual display (Lehrer, Vaschillo, & Vaschillo, 2000). According to a summary 
of the HRV biofeedback literature by Wheat & Larkin (2010), HRV biofeedback has 
been shown to significantly reduce cardiovascular mortality and hypertension in adults. 
Progressive muscle relaxation and relaxation training in combination with HRV 
biofeedback has also demonstrated reductions in cardiovascular risk and hypertension 
among adults as well (Wheat & Larkin, 2010). This is highly pertinent given the relation 
between AD and cardiac autonomic dysfunction, the high rate of cardiac events among 
older adults, and the prevalence of hypertension among older adults.   
Pharmacological interventions may also help to improve cardiac autonomic 
function as well. Certain blood pressure medications such as antihypertensives (beta 
blockers) have been shown to improve high frequency power and cardiac autonomic 
function after eight weeks among adults diagnosed with hypertension (Pavithran, 
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Prakash, Dutta, & Madanmohan, 2010). Therefore, individuals who present with 
parasympathetic depression following a HRV recording may be referred to a physician 
for a medication evaluation. The impact of the prescribed medication on the autonomic 
nervous system could be easily monitored via standardized pre/post HRV recordings 
using normalized units.   
Other potential risk factors associated with cardiac autonomic dysfunction (e.g., 
parasympathetic depression) include an increased risk for falls (American Geriatrics 
Society, 2010; Melillo, Jovic, De Luca, Morgan, & Pecchia, 2015). This is a major 
problem for older adults as one in ten falls results in serious injury and up to one in five 
in a fracture (Tinetti, 2003). Individuals with autonomic dysfunction and hypertension are 
also at higher risk for experiencing postural (orthostatic) hypotension which is a well-
known risk factor for falls among the elderly (American Geriatrics Society, 2011). The 
use of Donepezil has also been shown to cause orthostatic hypotension in some 
individuals as well (Bordier, 2006). Orthostatic hypotension is defined as a decrease in 
systolic blood pressure of 20 mmHg (or 20%) or more when the individual transitions 
from a supine to standing position (Tinetti, 2010). In the present study, the AD group 
showed greater increases in low frequency power compared to healthy controls when 
engaging in the orthostatic challenge (supine to standing). Previous research has indicated 
a relation between increased sympathetic nervous activity (low frequency power) and 
hypertension (Melillo, Jovic, De Luca, Morgan, & Pecchia, 2015). Although blood 
pressure was not measured in the standing position, it is possible that the AD group 
experienced greater fluctuations in blood pressure (e.g., hypertension) following the 
orthostatic challenge. Therefore, identifying cardiac autonomic dysfunction among older 
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adults via non-invasive HRV measures and providing interventions to improve cardiac 
autonomic function may reduce the likelihood of a fall. Interventions which have been 
shown to reduce the likelihood of falls among older adults include medication 
management, increased fluid intake, physical therapy (PT), increased exercise, and deep 
breathing (American Geriatrics Society, 2011; Jáuregui-Renaud, Márquez, Hermosillo, 
Sobrino, & Lara, et al., 2003).  
Limitations of the Current Study and Suggestions for Future Studies 
  There are various limitations to the current study, which warrant discussion. 
Firstly, although the sample size identified by the power analyses was met for both 
supine and standing positions, previous studies have used slightly larger samples to 
assess changes in HRV and obtained significant results (Da Costa Dias Dias et al., 2013; 
Masuda & Kawamura, 2003; Siepmann et al., 2006; Toledo & Junquiera, 2008; Zulli, et 
al., 2003). Results from the ANCOVA also indicated a medium effect for the LF/HF 
Ratio (log10) between group differences. The mean LF/HF Ratio (log10) reflected 
greater sympathetic dominance (larger LF/HF ratios) in both supine and standing 
positions at sessions 1, 2 and 3 among the AD group in comparison to the healthy control 
group.. However, based on the small sample used, this statistic was interpreted with 
caution given the potential for error variance within a small sample. The results from the 
present study do however indicate the need for larger controlled trials to further 
investigate the cardiovascular effects of Donepezil. One of the drawbacks of the small 
sample used in this study was the impact of variable scores on the mean of each HRV 
index. Using a larger sample would reduce the likelihood of more variable scores 
impacting the means of each index and increase the likelihood of detecting a statistical 
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significance. Secondly, it is difficult to determine the extent to which Donepezil may 
improve cardiac autonomic function compared to individuals with AD who are not taking 
Donepezil. Having a third comparison group (an AD group who are not taking 
Donepezil) or normative HRV data based on age, gender, and HRV positioning would 
provide more information of the extent to which Donepezil impacts the trajectory of 
cardiac autonomic dysfunction. However, recruiting individuals who are diagnosed with 
AD and who are not taking a ChEls would be challenging as the large majority of 
individuals diagnosed with probable AD are prescribed a cholinesterase inhibitor or a N-
Methyl-D-aspartate (NMDA) receptor antagonists (e.g., Namenda).  
Thirdly, given the increase in sympathetic nervous activity from the supine to 
standing position among individuals with AD, it is possible that baroreceptor reflex 
sensitivity is diminished among this population. Obtaining a blood pressure reading from 
AD participants in the standing position (e.g., measuring postural hyper/hypotension) 
may help identify any interference in the participants homeostatic mechanisms that help 
maintain blood pressure (Berntson, 1997). Fourthly, although transforming the RMSSD 
and LF/HF Ratio HRV indices using base 10 logarithm reduced the skewness and 
kurtosis of the distribution, interpretation of these indices became more difficult as the 
values were no longer expressed in normalized units and ratio values (LF/HF Ratio). 
However, Toledo & Junquiera (2008) used similar log transformations to correct non-
normal distribution among their HRV indices and used similar interpretations. Fifthly, 
future studies may want to explore whether the combination of a ChEls and N-Methyl-D-
aspartate (NMDA) receptor antagonist (e.g., Namenda) improves HRV above and beyond 
a ChEls alone. Sixthly, HRV was captured in the home environment for four of the AD 
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participants. Although obtaining HRV in the home was advantageous for recruitment 
purposes, this may have influenced HRV indices. Research has indicated that individuals 
with white coat hypertension (high blood pressure in the clinical setting) have a tendency 
towards higher levels of LF power and a propensity towards sympathovagal imbalance 
(Fagard, Stolarz, Kuznetsova, Seidlerova, & Tikhonoff, 2007). Based on this research, it 
is possible that individuals whose HRV was obtained in the clinical/laboratory setting 
were more likely to experience greater low frequency power compared to individuals 
whose HRV was captured in the home environment. Therefore this could be a potential 
confound, which was not accounted for in this study design. In order to reduce this 
confound in future studies, it is recommended that HRV be obtained in the same 
environment across and within groups. Lastly, the inclusion of neurocognitive measures, 
in addition to HRV measures, would provide a more accurate indication of the potential 
cholinergic benefits of Donepezil (Aricept®). As mentioned previously, cholinergic 
resources become increasingly deficient in individuals with AD resulting in 
neurocognitive impairment (Miur, 1996). Furthermore, the use of biomarkers such as 
volumetric magnetic resonance imaging (MRI) may help validate changes in HRV as a 
result of ChEl treatment. Overall, it appears that Donepezil’s effect on cardiac function in 
patients with Alzheimer’s disease is limited and requires further exploration.  
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APPENDIX A 
  Phone Screen 
Donepezil’s Effect on Cardiac Function in Patients with Alzheimer’s Disease 
Through an In Vivo, Non Invasive Measure of Peripheral Neuro-cholinergic 
Function: Relation to Therapeutic Efficacy 
Name:___________________________  
To be read to subject before screening questions: We are calling from Eastern 
Virginia Medical School regarding the research study that you expressed interest in. We 
wanted to see if you would be interested in participating in a research study that is 
examining the relation between heart and brain function and potential effects of 
medications on these functions. Your involvement in the study would last for 6 months 
with a total commitment of about 5 hours over that time. We are collecting several 
measures at session 1 and following up with similar measures during session 2 and 
session 3. This information is being asked to determine your eligibility in our research 
study, this information will not be used other than for the purposes of this research study. 
If you decide not to participate or for some reason are ineligible to participate, this 
information will be destroyed. Does this sound like something you would like to 
participate in?  (If no, thank the person for their time. If yes, ask the following screening 
questions. If the potential subject is determined ineligible for any of the screening criteria 
below, please provide the explanation for their ineligibility presented in italics below 
each screening question.) 
1. How old are you?__________________  
If not between the ages of 65-85 
[I am sorry at this time we are looking for subjects between the ages of 65-85, but thank 
you for your time and interest] 
2. How would you describe your ethnic background?____________________________ 
3. Do you have any assistive devices such as a pacemaker? Y N  
[I am sorry, we are unable to have people with any electrical assistive devices such as 
yours, because it can send a false signal when measuring heart rate, but we thank you for 
your time and interest] 
4. Have you ever had a stroke or TIA (Transient ischemic attack, or “mini stroke”), 
 Y N Date:___________ 
[I am sorry, we are unable to have people who have had a stroke previously because a 
stroke can affect measures that we are collecting, but we thank you for your time and 
interest] 
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5. Have you ever been diagnosed with arrhythmias (irregular heart rate) or vascular 
dementia (loss of mental function due to interruption of blood flow to the brain such as a 
stroke or heart attack)?  Y       N  
[Arrhythmia and vascular dementia can interfere with the measures that we are 
collecting.] 
6. Are you currently taking any medication? Y N 
 Which ones?_______________________________________________ 
not to be taking certain psychotropic medications (e.g., tricyclic antidepressants, selective 
serotonin reuptake inhibitors (SSRI’s), anticonvulsants, or antipsychotics). [Some 
medications can interfere with the measures we are taking, but thank you for your 
interest and time] 
7. Have you ever been diagnosed with cancer?  Y N  
Within the last year?     Y       N 
 
Were you under any treatment for cancer?   Y N  
Within the last year?      Y       N 
[Treatments for cancer can often interfere with the measures we are taking, so we are 
unable to have you participate in the study, but thank you for your time and interest] 
8. Have you ever been diagnosed with Kidney or Liver Disease?    Y N 
[Certain illnesses and diseases may interfere with nerve conduction in some of the 
measures we are collecting] 
9. Have you ever been diagnosed with a neurological illness? (ex. Multiple sclerosis or 
Parkinson’s Disease)          
          Y N 
[Certain illnesses and diseases may interfere with nerve conduction in some of the 
measures we are collecting] 
10. Do you suffer from significant hearing, sight, or sensory impairment?   Y    N 
Please describe:________________________________________________________ 
_____________________________________________________________________ 
[Impairment of vision, hearing, and other sensory functions may interfere with your 
ability to complete the testing required for this study]     
    
11. How far did you get in school? _____________ 
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12. Have you ever been hospitalized for a psychiatric problem?  
Have you ever been diagnosed with a psychiatric illness?    Y N 
 Which one?_______________________________________________ 
 When?___________________________________________________ 
 Were you given any medications for treatment?   Y N 
 Which ones?_______________________________________________ 
Must have no lifetime history of certain psychiatric symptoms or illnesses (including 
psychotic or delusional symptoms, bipolar disorder and schizophrenia).  
[Unfortunately we are unable to accept people who suffer from these diseases due to the 
possible interference in the measures we collect during the study] 
13. On average about how many alcoholic beverages do you consume in a week? ______ 
 (One beverage is equal to a 12oz. beer, 5 oz. Wine, or 1.5 oz of hard liquor) 
14. Have you ever had a concussion or head injury?    Y N 
 How many? _______________ 
 When? ___________________ 
Is subject eligible?  Y N 
Yes: Well, Mr/Mrs. ___________ it appears you would be a good candidate for this 
study, would you be able to come in for the first visit on________? At_______. This first 
visit takes about 1 hour and 30 minutes to complete so please wear comfortable clothes. 
You will come into our office and be given informed consent which details the study and 
you can determine if the study is right for you. If you decided that you would like to 
participate, you will at that time have a medical history interview and EKG. We will then 
administer a series of neuropsychological tests. [Be sure to gather home contact 
information] 
No: I am sorry but you are not eligible at this time to participate in this study. We 
appreciate your time and interest.  
Criteria:  
a) Meets age criteria and reports no clinical history of severe and chronic diseases 
affecting general health (cancer or treatment for cancer [within the past year], 
neurological disorders [e.g., multiple sclerosis], chronic kidney or liver disease, stroke or 
cerebrovascular events or disease) 
b) Is fluent in English (i.e., have commonly used English in everyday speaking and 
reading for at least 10 years) 
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c) Has no electronic assistive devices that may interfere with measuring HRV 
d) Does not have current substance dependence  
e) Is not taking certain psychotropic medications (e.g., tricyclic antidepressants, 
anticonvulsants, or antipsychotics) 
f) Has no lifetime history of certain psychiatric symptoms or illnesses (including 
psychotic or delusional symptoms, bipolar disorder and schizophrenia) 
g) Does not suffer from significant hearing, sight, or sensory impairment 
h) Has no history of arrhythmias or vascular dementia 
i) Has not sustained any significant head trauma that may impair cognitive function 
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APPENDIX B 
Demographics/Socioeconomic Status Form 
A. PERSONAL INFORMATION (Please circle) 
1. Sex: 
  (1)    Male  
  (2)    Female  
2. Age: ________ 
3. Date of birth: _____/______/_____ 
     mm     dd         yy 
4. Racial categories:  
  (1) Caucasian, white      
  (2) African American, black      
  (3) Asian       
  (4)  Latino or Hispanic      
  (5)  Native American     
(6) Bi- or multiracial, please specify: _________________ 
(6)       Other, please specify: __________________________ 
 
5.  What is your current marital status?   
  (1) Married/living with partner    
  (2) Widowed      
  (3) Separated      
  (4) Divorced      
  (5) Single        
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6. Total family income (before taxes; including your income and your spouse or 
partner’s income): 
  (1) Less than $10,000/year  or  $0 - 833/month    
  (2) $10,000 - 14,999/year  or  $834- 1249/month   
  (3) $15,000 - 24,999/year  or $1250 - 2083/month   
  (4) $25,000 - 34,999/year  or $2084 - 2916/month   
  (5) $35,000 - 49,999/year  or $2917 - 4166/month    
  (6) $50,000 - 64,999/year  or $4167 - 5416/month   
  (7) $65,000 - 79,999/year   or $5417 - 6666/month    
  (8) $80,000 - 94,999/year  or $6667 - 7916/month   
  (9) $95,000 - 109,999/year or $7917 - 9167/month 
  (10) $110,000 - 125,000/year or $9168 - 10,416/month 
  (11) More than $125,000/year or more than 10,417/month 
 
7. Individual income (before taxes): 
 
  (1) Less than $10,000/year  or  $0 - 833/month   
  (2) $10,000 - 14,999/year  or  $834- 1249/month   
  (3) $15,000 - 24,999/year  or $1250- 2083/month   
  (4) $25,000 - 34,999/year  or $2084-2916/month   
  (5) $35,000 - 49,999/year  or $2917- 4166/month    
  (6) $50,000 - 64,999/year  or $4167 - 5416/month   
  (7) $65,000 - 79,999/year   or $5417 - 6666/month    
  (8) $80,000 - 94,999/year  or $6667 - 7916/month   
  (9) $95,000 - 109,999/year or $7917 - 9167/month 
  (10) $110,000 - 125,000/year or $9168 - 10,416/month 
  (11) More than $125,000/year or more than 10,417/month 
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B. EDUCATION/OCCUPATION 
 
8.  How far did you get in school?   
a.   Specify number of years attended school (PLEASE CIRCLE): This refers to 
the number of 
      full time (8-9 month) years of school. 
 
GRADE SCHOOL      HIGH SCHOOL 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
COLLEGE       POST GRADUATE 
 
13 
 
14 
 
15 
 
16 
 
17 
 
18 
 
19 
 
20 
 
21 
 
22 
 
23 
 
24+ 
 
b.   Education level (please circle highest level achieved/completed): 
 
(0)No High School diploma 
(1)GED 
(2)High School diploma 
(3)Technical training 
(4)Some college, no degree 
(5)Associate degree 
(6)Bachelors degree 
(7)Masters degree 
(8)MD/PhD/J.D./PharmD 
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10.  What kind of work do you do? (i.e., What is/was your job? Do you work outside 
of your home)? 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________ 
Main occupation  - if not working due to retirement, disability, or unemployment but 
worked at least 6 months in past 12 months [at 1 or more jobs] ask job questions about 
most recent job. 
 
11. Do you own your own business (or are you self-employed)?     
 Yes  No 
 
12. If currently employed, how many hours a week do/did you work?  ________ 
hours 
1 = FT (>= 35 hours/week)   
2 = PT (1-34 hours/week)   
 
13. How long have you/did you work in that occupation or profession? 
                        _________ years     __________ months                   
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APPENDIX C 
Lifestyle Behaviors Questionnaire Form 
 
1. How many caffeinated beverages (coffee, tea, sodas, etc.) do you consume each day?  
 
_________ 
(daily total)  
 
 
2. Have you ever used any of the following tobacco products?  
        
a.   Cigarettes:             No        Yes _________        Currently _________     Quit_______  
                                               (# of years)                        (# of years)            (year quit)          
 
 
b.   Pipe:                      No        Yes _________        Currently _________     Quit_______ 
                                                 (# of years)                        (# of years)            (year quit)           
   
  
c.   Cigar:                     No        Yes _________        Currently _________     Quit_______  
                                               (# of years)                        (# of years)            (year quit)           
        
 
d.   Chewing tobacco:  No        Yes _________        Currently ______           Quit_______  
                                                         (# of years)                  (# of years)               (year quit) 
  
e.   Snuff : Never     Occasionally or tried     Regular Use (# of yrs)   ______ 
                                                               
 
3. On average about how many alcoholic beverages do you consume in a week?             
________ 
 (One beverage is equal to a 12oz. beer, 5 oz. Wine, or 1.5 oz of hard liquor)        
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4. Did you drink any alcohol in the last week? NO          YES  
4a. We would like to know the number of alcoholic drinks you have  
had in the last week. Today is __________. Let’s begin with yesterday.  
 BEER  WINE  LIQUOR OTHER (SPECIFY)  
M _____  _____  _____  _____________ 
T _____  _____  _____  _____________ 
W _____  _____  _____  _____________ 
R _____  _____  _____  _____________ 
F _____  _____  _____  _____________ 
SA _____  _____  _____  _____________ 
SU _____  _____  _____  _____________    
         ____________   
                       (7 day total) 
5. At least once a week, do you engage in regular activity such as brisk walking, jogging, 
bicycling, swimming, etc., long enough to work up a sweat, get your heart thumping, or 
get out of breath? 
 ____  No.    Why not? 
__________________________________________________    
    
 ____ Yes.    How many times per week? _______  
             
In what type of activities do you engage?  _________________ 
6. Approximately how many hours do you spend each week participating in physical 
activities such as walking, playing a sport, ( golf, tennis, etc.), physical therapy, or group 
exercises such as water aerobics? 
__________ 
(number of hours) 
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APPENDIX D 
Medical History Checklist Form 
Do you have or have you had any of the following? (PLEASE CHECK ONE) 
 
 
 
YES 
(1) 
 
NO 
(0) 
 
DON’T 
KNOW 
(-3) 
 
Heart or Blood Vessels  
   
 
1. High blood pressure (hypertension) 
 
(  ) 
 
(  ) 
 
(  ) 
 
2.   Heart attack (myocardial infarction, coronary occlusion or 
coronary thrombosis) 
 
(  ) 
 
(  ) 
 
(  ) 
 
3.   Angina (chest pain brought on by exertion) 
 
(  ) 
 
(  ) 
 
(  ) 
 
4.   Heart bypass surgery 
 
(  ) 
 
(  ) 
 
(  ) 
 
5.  Heart balloon angioplasty, stent 
 
(  ) 
 
(  ) 
 
(  ) 
 
6.   Congestive heart failure 
 
(  ) 
 
(  ) 
 
(  ) 
 
7.   Valve problems (heart murmur or leaky valve) 
 
(  ) 
 
(  ) 
 
(  ) 
 
8.   Heart pacemaker 
 
(  ) 
 
(  ) 
 
(  ) 
 
9.   Rheumatic fever with involvement of heart 
 
(  ) 
 
(  ) 
 
(  ) 
 
10. Abnormal heart rhythm (e.g. atrial fibrillation) 
 
(  ) 
 
(  ) 
 
(  ) 
11. Other (Specify: _______________________________) (  ) (  ) (  ) 
Brain  
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12. Stroke (cerebrovascular accident) (  ) (  ) (  ) 
 
13. TIA or transient ischemic attack (brief stroke that completely 
resolved within 24 hours) 
 
(  ) 
 
(  ) 
 
(  ) 
 
14. Convulsions, fits or seizures, epilepsy 
 
(  ) 
 
(  ) 
 
(  ) 
 
15. Head injury or concussion or spinal cord injury, how many? 
 
(  ) 
 
(  ) 
 
(  ) 
 
16. Loss of consciousness, how long? 
 
(  ) 
 
(  ) 
 
(  ) 
 
17. Parkinson’s disease, Multiple Sclerosis or Muscular 
Dystrophy 
 
(  ) 
 
(  ) 
 
(  ) 
 
18. Other (Specify:________________________________) 
 
(  ) 
 
(  ) 
 
(  ) 
 
Other Diseases  
 
YES 
(1) 
 
NO 
(0) 
 
DON’T 
KNOW 
(-3) 
 
19. Diabetes (high blood or urine sugar) 
 
(  ) 
 
(  ) 
 
(  ) 
 
20. Kidney problems (nephritis, kidney infection, kidney stones) 
 
(  ) 
 
(  ) 
 
(  ) 
 
21. Surgery (type: ______________________________) 
 
(  ) 
 
(  ) 
 
(  ) 
 
22. Cancer (site:___________________________) 
 
(  ) 
 
(  ) 
 
(  ) 
 
23. Asthma 
 
(  ) 
 
(  ) 
 
(  ) 
 
24. Other lung problems (TB, emphysema, pleurisy, chronic 
bronchitis, or other problems) 
 
(  ) 
 
(  ) 
 
(  ) 
 
25. Thyroid condition 
 
(  ) 
 
(  ) 
 
(  ) 
 
26. Liver disease (hepatitis, cirrhosis or other problems) 
 
(  ) 
 
(  ) 
 
(  ) 
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27. Arthritis 
 
(  ) 
 
(  ) 
 
(  ) 
 
28. Hives, hay fever, or other allergies 
 
(  ) 
 
(  ) 
 
(  ) 
 
29. Other major disease (specify: ________________________) 
 
(  ) 
 
(  ) 
 
(  ) 
 
30. Have you ever been hospitalized? 
 
(  ) 
 
(  ) 
 
(  ) 
 
 
Please indicate whether the following are true: 
 
YES 
(1) 
 
NO 
(0) 
 
31. Full use of arms, hands, and fingers 
 
(  ) 
 
(  ) 
 
32. Full use of legs and feet 
 
(  ) 
 
(  ) 
 
33. Good eyesight (when wearing glasses or contact lens) 
 
(  ) 
 
(  ) 
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APPENDIX E 
Medication Update Form 
 
1. Are you currently taking Aricept (donepezil)?   Yes_____           No_____ 
 1a. If so how much do you take?    __________(mg)  
 1b. How often do you take Aricept? (twice a day, once a day, etc.)  
 ______________________________________________________ 
 ______________________________________________________ 
 ______________________________________________________ 
 
 1c. What time did you last take Aricept? (this morning, last night, etc.) 
 _______________________________________________________ 
 _______________________________________________________ 
 _______________________________________________________ 
 
Note any change in dosage or instructions for administration here. 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
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2. Are you currently taking any other medications that require a prescription from a 
doctor? 
Yes _____   No______ 
Medication Name Purpose Dosage (mg)  and 
Frequency 
Last taken 
    
    
    
    
    
    
    
 
2. Do you take any supplements or over the counter medications?  
 (For example, a multiple vitamin, vitamin C, calcium, iron, St. John’s wort, 
glucosamine, ginkgo, allergy         
 pill, cold medication, antacid or , laxative) 
Yes_____    No_____  
Supplement Name Dosage (mg) and 
Frequency 
Last taken 
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3. Since your last session, have you taken aspirin or an over-the-counter pain 
medications  
 (ibuprofen, Tylenol, etc)? 
 
Yes_____   No_____  
 
Medication Name Purpose Dosage (mg) and 
Frequency 
Last taken 
    
    
    
 
Notes: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
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APPENDIX F 
Physical and Biological Assessments 
Height:  __________ 
Weight: __________ 
Blood Pressure 
Cuff Size:  _________ 
 1st:   _________ 
 2nd:   _________ 
HRV measurement: 
 Time: __________ 
 Date: __________ 
 
Respiration: 
 Minute 1: 
Total Rate for minute:         ___________ 
 Minute 3:  
Total Rate for minute:  ___________ 
 
Average of two readings:              ___________ 
  • Divide by 60:  ___________ 
  • ADD (0.03)    ___________ 
  • SUBTRACT (0.03)   ___________ 
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APPENDIX G 
Power Analysis 
Supine: 
F tests - ANOVA: Repeated measures, between factors 
Analysis: A priori: Compute required sample size  
Input: Effect size f = 0.82 
 α err prob = 0.05 
 Power (1-β err prob) = 0.80 
 Number of groups = 2 
 Repetitions = 3 
 Corr among rep measures = 0.5 
Output: Noncentrality parameter λ = 12.103200 
 Critical F = 4.964603 
 Numerator df = 1.000000 
 Denominator df = 10.000000 
 Total sample size = 12 
        Actual power        =   0.879100 
 
 
Standing: 
F tests - ANOVA: Repeated measures, between factors 
Analysis: A priori: Compute required sample size  
Input: Effect size f = 0.65 
 α err prob = 0.05 
 Power (1-β err prob) = 0.80 
 Number of groups = 2 
 Repetitions = 3 
 Corr among rep measures = 0.5 
Output: Noncentrality parameter λ = 10.140000 
 Critical F = 4.600110 
 Numerator df = 1.000000 
 Denominator df = 14.000000 
 Total sample size = 16 
 Actual power =  0.841313 
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